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Acute otitis media (AOM) is the most common bacterial infection in children for which parents 
seek medical advice (1). Acute otitis media commonly presents with fever, ear pain, and 
hearing impairment. Common otopathogens include Streptococcus pneumoniae, non-typeable 
Haemophilus influenzae (NTHi), and Moraxella catarrhalis (2,3). Colonisation with these 
organisms at a young age is associated with an increased risk of developing AOM in young 
children (1). Despite vaccination against strains of S. pneumoniae and NTHi, there has been 
little impact on the overall prevalence of otitis media. The lack of vaccine impact is primarily 
due to an increase in disease attributable to non-vaccinated strains (2,4). Management of non-
resolving AOM involves the use of broad-spectrum antibiotics. However, frequent and 
inappropriate use of antibiotics is associated with increasing antimicrobial resistance and 
facilitates colonisation with resistant strains of pathogenic species (5,6). Thus, in light of the 
high prevalence and the considerable burden of AOM in the community, new strategies for 
preventing recurrent AOM are needed.  
Aims: 
1. To review the literature on the use of probiotics in the prevention of AOM.  
2. To determine the efficacy of probiotics against otopathogens.  
3. To assess the ability of probiotics to colonise the nasopharynx.  
Methods: 
A literature review was carried out across databases, Medline, EMBASE, PubMed and 
Cochrane, using keywords related to probiotics, otitis media and ear infection. The search 
phrases were searched as medical subject headings (MeSH), and as a subject, terms with 
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possible endings were denoted with “*” to expand the search. The literature title and the 
abstract were then screened and related articles were obtained and critically analysed. Meta-
analysis was then conducted on homogenous data to determine the overall benefit of probiotics 
on AOM.  
To determine the efficacy of Streptococcus salivarius K 12 on the inhibition of otopathogens. 
Isolates of otopathogens from otitis-media prone children were cultured and plated against S. 
salivarius K12.  
To determine the ability to colonise the nasopharynx, fifty healthy adult volunteers were 
recruited and randomised to S. salivarius given orally and nasally. Pre-colonisation swabs were 
taken followed by a course of oral antibiotics. A two-week course of probiotics was provided 
to the volunteers. One week after the completion of probiotics, the individuals were swabbed 
again. Both swabs were analysed with real-time quantitative polymerase chain reaction. (RT-
qPCR). 
Results: 
From the literature review, thirteen studies were identified. Overall, the study designs were 
heterogeneous and were of moderate quality. Five of the studies had enough similarity in 
population selection, methodology and outcome measure for meta-analysis. The conglomerate 
data from these five studies showed no demonstrable prophylactic effect for the use of 
probiotics on AOM. Probiotics species varied widely in the literature and also in the route of 
administration. The evidence for the use of probiotics in AOM was therefore conflicting and 
insufficient to support their clinical use in the prevention of AOM.  
In the trial of probiotics versus otopathogens isolates, 107 known otopathogens isolates from a 
previous study lead by Mills et al. were culturable and identifiable. When tested against the 
bacteriocin-like inhibitory substance (BLIS) from S. salivarius K12, 48% had demonstrable 
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inhibition. Overall, complete inhibition of all S. pneumoniae was witnessed with partial to no 
inhibition of other known otopathogens. 
The colonisation trial did not yield sufficient data to suggest or refute the ability of the S. 
salivarius to colonise the nasopharynx or alter its microflora. However, it has been 
demonstrated that the tolerability of the nasal route of probiotics administration was not as 
good as previously thought.  
Significance: 
The available literature on the use of probiotics for AOM is of low quality and quantity. 
Although S. salivarius is a potential probiotic choice for AOM prophylaxis, it only 
demonstrates inhibition in less than half of the otopathogen isolates. Therefore, it is unlikely to 
be effective, if used alone. The colonisation trial was unable to be completed as proposed due 
to unanticipated complications, but it did hint that the tolerability and safety of S. salivarius 
K12 need to be studied further.   
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CHAPTER 1 - BACKGROUND 
a. Introduction 
The human ear is composed of 3 distinct sections that are anatomically and physiologically 
different from one another. The ear consists of the external, middle and inner components. The 
external ear constitutes the pinna and the external ear canal is linked with the middle ear by the 
tympanic membrane (eardrum). The middle ear is a ventilated space between the tympanic 
membrane and the inner ear. This space contains the ossicles (the malleus, incus and stapes), 
as well as the ligaments that suspend these ossicles and the folds of mucosa that dictate the 
pathway of ventilation (7). The ossicles are small bones connected serially, which act to 
transmit the vibrations of the sound waves from the eardrum to the inner ear, through the oval 
window. The inner ear is composed of the cochlear and the vestibular apparatus. (see Figure 1-
1) 
 
Figure 1-1: General anatomy of the ear.  
© The Staywell Company, LLC (Southern Ohio Medical Centre) (Used with permission) 
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Functionally, the external ear funnels the sound waves onto the tympanic membrane and allows 
it to vibrate. The vibration of the tympanic membrane is carried across the middle ear cleft via 
the ossicles and to a smaller degree, by direct transfer through the air. During this process, the 
vibrations are augmented by the middle ear mechanics so that the intensity of vibration is 
amplified before transmitting into the inner ear via the oval window. The inner ear serves to 
transduce the mechanical waveform of the vibration from the sound waves into an electrical 
signal via the organ of Corti, and the signal is conducted centrally via the cochlear nerve. 
There are distinctive differences between the three components of the ear. Therefore, 
conglomerating infection and inflammation of the human ear as “ear infection” is inaccurate 
and ineffective. Although each of the components of the ear can be subjected to infection and 
inflammation, the underlying aetiology and causative factors in each of the components is 
dissimilar. The treatment is, therefore, very different for each component of the ear. 
Furthermore, inflammation of each of the components of the ear can be further sub-classified 
into various subtypes characterised by a combination of the duration, aetiology and anatomical 
destruction as a result of inflammation. 
Middle ear inflammation (otitis media) will be the focus of this master’s thesis and will be 
discussed further. Infection and inflammation of the other components of the ear are beyond 
the scope of this thesis. 
b. Anatomy and physiology of the ear. 
i. Anatomy of the middle ear 
The middle ear cleft is a ventilated space situated on the inferior surface of the temporal bone. 
It is bound laterally by the scutum of the temporal bone, tympanic membrane and the tympanic 
bone from top to bottom. Medially the middle ear cleft is bound by the otic capsule and the 
bony labyrinth. Anteriorly, it is bound by the tympanic bone and posteriorly, by the mastoid 
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portion of the temporal bone (8). Superiorly, the middle ear is separated from the middle cranial 
fossa by the tegmen tympani. Inferiorly, the middle ear cleft floor is made up partly by the 
jugular bulb.  
The middle ear cleft communicates anteriorly with the nasopharynx via the Eustachian tube 
and posteriorly with the mastoid sinus via the aditus ad antrum. The cleft is further sub-divided 
into various regions by its relations to the tympanic membrane. Namely, these are 
epitympanum, mesotympanum, hypotympanum, protympanum and the retrotympanum (8). 
Respiratory type epithelium lines the middle ear cavity and the mastoid air cell system (9). The 
arterial supply for the middle ear is composed of a complex array of anastomoses from the 
superficial petrosal, superior tympanic, subarcuate, internal auditory, stylomastoid and anterior 
tympanic arteries (10). 
Suspended by ligaments, the ossicles span the middle ear cleft. The malleus is placed most 
laterally, its handle is firmly enveloped by the layers of the tympanic membrane. It articulates 
with the incus via a synovial joint in the epitympanum. The incus has two processes. The long 
process extends inferiorly into the mesotympanum to articulate with the stapes in another 
synovial joint. The stapes passes medially via two crura to end in the stapes footplate. The 
footplate is firmly secured to the oval window of the otic capsule. The ossicular chain transmits 
and amplifies the signals through the middle ear cleft and into the inner ear.  
ii. Physiology of the middle ear 
The middle ear acts as a signal transducer and amplifier, conducting the mechanical energy of 
the sound waves to the inner ear where the signal is then transformed into nerve impulses. 
There are two main ways in which the sound travels: 1) tympano-ossicular system (ossicular 
coupling) and 2) direct sound transmission via the round and oval windows (acoustic coupling) 
(11). In the normal state, with an aerated middle ear cavity, tympano-ossicular coupling takes 
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a predominant role in transmitting the energy. In the normal middle ear, the acoustic coupling 
is in the magnitude of 60 decibels (dB) lower than the ossicular coupling. However, in various 
diseased states of the middle ear, these two mechanisms are affected, and conductive hearing 
loss varies from 5 to 60dB (11).  
iii. Anatomy and physiology of the Eustachian tube 
The Eustachian tube connects the protympanum of the middle ear cavity from each side to the 
lateral wall of the nasopharynx. The length varies from 31-44mms in adults and slants from the 
middle ear towards the nasopharynx at an average angle of 35 degrees down from the horizontal 
plane (12). The tube consists of a lateral one-third bony portion and a medial two-thirds 
fibrocartilaginous portion. The osseous portion, formed by the petrous temporal bone, is fixed 
and is not involved in dynamic physiological function. The cartilage consists of a tall medial 
lamina (5.1mm) and a short lateral lamina (1.8mm) (12). This height discrepancy between 
lateral and medial lamina plays a crucial role in the physiology of the Eustachian tube. The 
tubal cartilage has higher elasticity in adults when compared to children (12). Furthermore, 
children have less muscular opening function lea more negative middle ear pressures (13). The 
relative dysfunction of the Eustachian tube to secondary to young age appears to result from 
size and shape differences in the cartilage and changes in the position of the levator and tensor 
veli palatini muscles (14). Attached to the short lateral lamina is the origin of the medial head 
of the tensor veli palatini muscle (15). The hyaline cartilage is suspended from the skull base 
by medial and lateral suspensory ligaments.  Contraction of the medial head of the tensor veli 
palatini muscle leads to lateralisation of the lateral lamina and thereby opening the upper 
portion of the Eustachian tube (12,15). 
Contraction of the lateral head of the tensor veli palatini closes the inferior portion of the 
Eustachian tube. Thus, the dynamic action of the tensor veli palatini assists in the ventilation 
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of the middle ear via the superior portion of the Eustachian tube, whilst facilitating the drainage 
of mucus by the inferior portion of the Eustachian tube. Closure of the Eustachian tube is 
facilitated passively by the lateral fat pad of Ostmann and actively helped by the 
salpingopharyngeus via its attachment to the medial lamina. The competence of the Eustachian 
tube is essential as it prevents the migration of the microflora of the nasopharynx into the sterile 
middle ear cavity. 
 
Figure 1-2: Anatomy of Eustachian tube. Abbreviations: ofm = Ostmann’s fat pad (medial), 
tslm = medial tubal suspensory ligament, tsll = lateral tubal suspensory ligament, rsc = 
Rudinger’s safety canal, tcl = tubal cartilage (lateral lamina), tcm = tubal cartilage (medial 
lamina), ofl = Ostmann’s fat pad (lateral), tvpl = tensor veli palatini (lateral), lvp = levator 
veli palatini, mpm = medial pterygoids muscle, tvpm = tensor veli palatini (medial), ph = 
pterygoid hamulus, b = bursa. 
© Elsevier (used with permission) 
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c. Otitis media 
i. Definitions of otitis media 
Otitis media is inflammation of the middle ear, which could be attributable to different causes, 
but most often to infection. Otitis media has various subtypes: (16,17) 
- Acute: 
o Acute otitis media (AOM) is defined by the presence of fluid in the middle ear, 
accompanied by signs of acute illness.  
- Chronic: 
o Otitis media with effusion (OME) - the presence of fluid in the middle ear 
without signs or symptoms of acute infection lasting for more than 12 weeks. 
o Chronic suppurative otitis media (CSOM) - chronic inflammation of the middle 
ear that persists for at least 6 weeks and may be associated with otorrhea through 
the tympanic membrane, via a perforation, myringotomy or tympanostomy tube. 
o Adhesive otitis media - when the tympanic membrane becomes atelectatic 
through recurrent inflammation, is medialised and adherent to the medial wall 
of the middle ear cleft. 
o Cholesteatoma – disruption of the regular squamous epithelial migration on the 
lateral surface of the tympanic membrane, leading to the build-up of keratinous 
debris in the middle ear cavity. 
Whilst the afore categorisation appears discrete, the manifestation of childhood respiratory 
infection is more of a continuum (18), and thus definition varies significantly between authors.  
ii. Pathophysiology of AOM 
The pathogenesis of acute otitis media is multifactorial (19–21). However, Eustachian tube 
dysfunction plays a significant role in its aetiology. Causes of Eustachian tube dysfunction are 
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categorised as anatomical, physiological, and environmental factors. The Eustachian tube 
functions to equalise the pressure of the middle ear with the ambient atmospheric pressure, to 
protect the sterility of the middle ear from the nasopharyngeal flora and to facilitate the 
mucociliary clearance of middle ear secretions to the nasopharynx. Therefore, Eustachian tube 
dysfunction disrupts the maintenance of normal middle ear pressure, protected sterility and 
mucociliary clearance of secretions.  
Anatomically, compared to their older counterparts, infants and younger children have shorter, 
broader and more horizontal situated Eustachian tubes (21,22). These features make the middle 
ear more easily accessible to the microflora of the nasopharynx. Thus, otopathogens harboured 
in the nasopharynx are a significant risk factor for AOM.  
The Eustachian tube is a dynamic structure, governing the opening and closing are the 
surrounding muscles that are intimately associated with chewing and swallowing. Therefore, 
physiological disturbances, as seen in children with cleft palate and other craniofacial 
abnormalities, have an increased tendency to have recurrent acute otitis media (rAOM) or 
CSOM.  
Environmental factors are known to trigger an inflammatory response in the nasal cavity and 
also of the nasopharynx. Hence, children with exposure to specific environments are at 
increased risk of rAOM. These factors are covered in the later paragraph, detailing the risk 
factors of AOM. 
The pathway of pathogenesis of AOM typically involves exposure to an upper airway infection 
or allergic reaction, leading to congestion of the nasopharyngeal mucosa and the Eustachian 
tube opening. The mucosal congestion, in turn, impairs the function of the unfavourable 
anatomy of the Eustachian tube in children, resulting in the accumulation of fluid and negative 
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pressure in the middle ear. The microorganisms that normally colonise the nasopharynx 
colonises this pocket of fluid collection resulting in acute suppurative infection. 
A couple of theories have been postulated regarding the aetiogenesis of the middle ear fluid in 
AOM (23). The more modern mechanism (inflammatory theory) proposes that the middle ear 
effusion is a sequela to the induction of the inflammatory pathway from bacterial infection. 
This leads to extravasation of intravascular proteins, resulting in water migration and the 
development of a middle ear effusion. Due to the congested Eustachian tube, this fluid is unable 
to egress and accumulates in the confined space (24). The negative pressure of the tympanic 
cavity (ex-vacuo theory) proposes the gradual depletion of middle ear nitrogen and oxygen 
from insufficient ventilation, leads to the formation of a transudate, and through Eustachian 
tube dysfunction accumulates in the middle ear space and is secondarily infected by bacteria.  
iii. Pathophysiology of OME and CSOM 
Chronic otitis media may follow acute infection if the underlying pathophysiology is not 
corrected, multiple hypotheses on its pathophysiology have been postulated (22). 
The inflammatory hypothesis (25) postulates that chronic inflammation and immune reaction 
from the perpetuating middle ear infection stimulate the production of pro-inflammatory 
cytokines. The chronically activated inflammatory response results in localised vasodilation 
leading to increased gaseous exchange in the middle ear cavity. In turn, this leads to a pressure 
differential across the eardrum, resulting in progressive retraction pocket formation and 
atelectasis of the tympanic membrane. Although the link between atelectasis, retraction pocket 
and cholesteatoma formation is complex (26,27), inflammation appears to be a common factor. 
Associated with the increase in pro-inflammatory cytokine formation is the stimulated 
production of mucin within the tympanic cavity, which further impairs the drainage and 
ventilation via the Eustachian tube.  
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The role of biofilm production by bacteria in OME has been increasingly recognised (28). 
Organisms that are embedded in an intricate three-dimensional lattice of the surrounding 
extracellular matrix of polysaccharides, nucleic acid and proteins, may be resistant to the host’s 
immune system and antibiotic therapy. Through inter-microbial symbiosis, biofilm formation 
also covers reduced metabolic demand for resources such as oxygen and nutrients; and through 
sharing of plasmids microorganisms in the biofilm adopts antibiotic resistance.  
Gastro-oesophageal reflux has also been thought to have a role in chronic otitis media. 
However, the direct causal mechanism has not been demonstrated (29). Likewise, the 
association of chronic otitis media and allergy have been identified, but the mechanism remains 
unclear (22).  
iv. Microbiology of otitis media 
AOM is a polymicrobial disease and often results as a complication of viral upper respiratory 
tract infection. The viral-bacterial interaction in the pathogenesis of AOM is complex. 
Although the majority of AOM is a coinfection of bacteria and viruses, bacteria or viruses alone 
are also capable of inducing AOM (30,31). Most types of respiratory viruses have the potential 
to cause otitis media, but respiratory syncytial virus and rhinovirus account for most of the 
viruses causing disease (20). Bacterial causes of AOM are also common and often culturable 
from the middle ear effusion through tympanocentesis (3). The most common otopathogens 
are Streptococcus pneumoniae (25%-50%), non-typeable Haemophilus influenzae (NTHi) (15-
30%), Moraxella catarrhalis (3%-20%), group A streptococcus and Staphylococcus aureus 
(2%-3%)(32).  
Streptococcus pneumoniae, also called pneumococcus, is an encapsulated gram-positive 
diplococcus. It is an extracellular organism, usually a commensal organism in the 
nasopharyngeal mucosa, but it can manifest as an opportunistic pathogen (33). The carrier rate 
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for S. pneumoniae in childhood varies between 27% and 65%, with younger children 
demonstrating a higher rate of carriage, while in the adult population carriage is less than 10% 
(34). S. pneumoniae can be virulent once it gains entry into the body cavity that is usually 
sterile and can cause infective inflammatory diseases, such as otitis media, community-
acquired pneumonia, sepsis and meningitis. Transmission of pneumococcus is by host-to-host, 
as there is no known vector in the transmission pathway. Transmission is more frequent during 
colder months due to copious and thicker airway secretions and the increased likelihood of 
concurrent viral infection, especially influenza-A virus. With increases in upper airway 
secretions from cold weather and influenza virus (35), the likelihood of pneumococcus 
shedding increases. The extent to which pneumococcus spreads via airborne transmission 
versus contact-dependent transmission is still unclear (33). However, the organisms’ ability to 
survive for many days on inorganic surfaces is well documented (34). Acquisition of 
pneumococcus by a new host is facilitated by its IgA1 protease production, rendering the 
mucosal antibody’s defence ineffective. Once acquired, nasopharyngeal carriage is 
fundamental to the development of invasive disease. The pneumococcus evades entrapment by 
upper respiratory tract mucus, due to the negatively charged capsule repelling the glycoproteins 
within the mucin. Once the organism gains proximity to the nasopharynx, the surface adhesin 
molecules anchor onto the nasopharyngeal mucosa. The development of invasive 
pneumococcal disease is thought to be related to local inflammation and breaking down of the 
barrier integrity, leading to the organism gaining access into the bloodstream, resulting in 
bacteraemia or meningitis.  
Haemophilus influenzae is a gram-negative coccobacillus that has encapsulated and 
unencapsulated sub-types. It is a common human commensal organism of the respiratory tract 
but can be an opportunistic pathogen. Encapsulated H. influenzae are typed by their capsular 
proteins and hence categorised into groups A to F. The unencapsulated strains lack the capsular 
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protein and are termed the NTHi. This group of organisms demonstrate more heterogeneity. 
Nonetheless, recent advances in polymerase chain reaction (PCR) techniques have allowed 
some sub-typing of NTHi by multilocus sequence characterisation (36). NTHi commonly 
causes opportunistic mucosal infections if the mucosal clearance mechanism is impaired or 
absent, resulting in otitis media or infective exacerbations of chronic obstructive pulmonary 
disease.  NTHi can form biofilms in the respiratory tract, therefore rendering itself protected 
against antibiotics and host immune systems. Other virulence factors of NTHi include the 
ability to down-regulate the host’s complement activation system as well as cellular immunity, 
which in turn reduces the membrane attack complex facilitated cell lysis and opsonised 
phagocytosis. Dampening of the humoral response is also becoming more recognised as a self-
protecting mechanism for NTHi (36). 
M. catarrhalis is the third most common bacterial pathogen causing acute otitis media. It is a 
gram-negative diplococcus that often co-exists with the host normal flora as a common 
commensal organism (37). Virulence factors include the ability to bind strongly to the extra-
cellular matrix of the respiratory epithelium, from its specialised ubiquitous surface protein; 
which anchors the organism securely to the collagen fibres of the matrix (38). This surface 
protein of M. catarrhalis also binds to tissue plasminogen and activates the degradation 
pathway for the complement activation system of innate immunity (37). These activities of the 
ubiquitous surface protein render the organism difficult to eradicate through the normal cilia 
mediated mucous clearance mechanism.  
v. Epidemiology of AOM 
Childhood ear infections are prevalent, and up to 85% of children by the age of three will have 
had at least one episode of acute otitis media (39). Up to 10-20% of children have recurrent 
attacks of acute otitis media, and up to 40% of these children will have more than six discrete 
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episodes of acute otitis media in a single 12 months period (20). There are multiple factors and 
characteristics of an individual that predispose them to have a higher risk of acute otitis media. 
These can be broadly separated into a host’s microbial load, the host’s immune system and 
environmental factors. Furthermore, some studies have demonstrated an increased rate of 
diagnosis of acute otitis media (40). This needs to be interpreted with caution, as it may 
represent increasing awareness and testing, and thus diagnosis, rather than a genuine increase 
in incidence.  
Gribben et al. in 2012 used a retrospective cohort to examine the epidemiology of acute otitis 
media in New Zealand (41). The group had included 19,146 children in the sample, with an 
incidence of 273 per 1,000 children per annum (27.3%; 95% CI 21.6% - 33.0%). The incidence 
of AOM was noted to decline with the increasing age of the children. Interestingly, there was 
no observed difference in incidence between Māori, Pacific and ‘Other’ ethnicities. In their 
cohort, antibiotic treatment was initiated in 2,653 AOM episodes (51%). Furthermore, 113 
(4.3%) of these children re-presented within three days of antibiotic therapy for persistent 
symptoms. Tympanic membrane perforation was the only complication noted, observed in 62 
(1%) episodes. 
vi. Risk factors for AOM 
The primary risk factor for otitis-media in children is younger age (40) but others are described 
below. Waldeyer’s ring is a collection of intra-mucosal lymphoid tissue of the upper 
aerodigestive tract and forms a primitive immune defence against upper airway pathogens (42). 
The lymphocytes of the Waldeyer’s ring produces secretory type immunoglobulin A and 
immunoglobulin G antibodies that reinforce the local host immunity. These innate antibodies 
act to reduce adherence of the pathogens onto the nasopharynx, therefore if deficient can lead 
to increased predisposition to acute upper airway infection and also of acute otitis media (43).  
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The genotype of an individual can also influence the propensity to develop otitis media. A 
study has shown higher concordance among monozygotic twins than dizygotic twins (44). 
Similarly, children with a family history of acute otitis media are found to have more than two 
and a half times the probability of having otitis media (39). However, the genetic interplay and 
the genotype to phenotype translation is complex and not fully understood. Many studies to 
date, from a combination of the murine and human models, have identified a multitude of gene 
loci to be in association with acute otitis media, these range from mild anatomical craniofacial 
differences to physiologically different host immune responses (20). Atopy (and its impact on 
the immune system) is one of the genetic factors that are associated with the development of 
AOM (45). Despite a lack of full understanding of the genetic inter-play in AOM, genomic 
studies have yielded essential themes, and those are 1) genetic changes leading to mild 
craniofacial abnormality can be associated with severe OM and 2) genetic alteration that led to 
failure to maintain a balance of pro-inflammatory and anti-inflammatory cytokines are often 
associated with severe otitis media (46). 
A child’s environmental exposure during early infancy and childhood also contributes 
significantly to the risk of acute otitis media. Meta-analysis pooling data from observational 
studies have identified significant predicators for acute otitis media. Breastfeeding for at least 
three months appear to be a preventative measure (47), whilst exposure to parental smoking 
(39), living in overcrowded households (48), and group day-care attendance (49), are other 
commonly associated adverse environmental factors for AOM. 
d. Preventative measures for otitis media  
i. Immunisation for the prevention of otitis media 
Immunisation or vaccination is a process first introduced in 1796 by Edward Jenner with 
smallpox (50). The process involves exposing the body’s adaptive immune system to non-
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virulent antigens of a particular pathogenic organism. This exposure leads to the body’s 
development of immunity, such that when the individual is exposed to pathogenic species at a 
later time, the immune system is more adapted to recruit and mount a more effective immune 
response to rid of the infective organism.  
Vaccines are broadly categorised into four main types (51): 
- Live-attenuated vaccine - use a weakened (or attenuated) form of the pathogen. 
- Inactivated vaccine - use the killed version of the pathogen. 
- Subunit, recombinant, polysaccharide, - use specific pieces of the pathogen — like its 
protein, sugar, or capsid. Conjugation is a modification combining a less immunogenic 
antigen to one that elicits a robust immune response. 
- Toxoid - use a toxin (harmful product) made by the bacteria that causes a disease. These 
create immunity to the parts of the bacteria that cause disease instead of the organism 
itself. 
Capsular polysaccharide (CPS) vaccine for pneumococcus has been available since the 1970s 
and was designed to target the known capsular antigens for pneumococcus. Whilst the 
polysaccharide vaccines are partially immunogenic in adults, they are unable to induce an 
antibody response in infants and children, the population for whom the vaccines were most 
needed (52). However, two independent groups had later discovered, that based upon the 
knowledge Avery et al. gained from a 1929 study, bacterial capsular polysaccharides can be 
very immunogenic when covalently bonded with a carrier protein (53). 
The mechanism by which the conjugate vaccine works for younger children has been recently 
reviewed (52,54). Capsular polysaccharide vaccines lack efficacy in children despite readily 
engaging with B cells and becoming internalised. However, due to the lack of affinity to bind 
with the major histocompatibility complex (MHC) and hence initiate T helper cell response, 
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the resultant immunity is short-lived. Conversely, in the conjugate vaccine, the carrier protein 
component is broken down and engages with the MHC, and in turn, triggers T helper cell 
response. The recruitment of T cell response then triggers the necessary release of cytokines 
and stimulation for the development of germinal centres, affinity maturation, clonal 
proliferation, and production of plasma cells and memory B cells. It is the formation of the 
memory B cells that then confers long-term immunity for the immunised individual. 
ii. Pneumococcus and vaccination  
S. pneumonia is the primary pathogen in bacterial acute otitis media in children. It is also a 
vaccine-preventable organism with multiple formulations of the vaccine available on the 
market. Pneumococcal conjugate vaccine (PCV) has been introduced since the early 2000s and 
has since made a significant difference in pneumococcal disease patterns (55). Over time, two 
PCVs containing a higher number of serotype-specific CPS started to replace the PCV7 vaccine. 
These were the 10-valent pneumococcal NTHi D-conjugate vaccine (PHiD-CV, Synflorix, 
GSK) and the 13-valent PCV (PCV13, Prevenar 13/Prevnar 13, Pfizer Inc.). These 
formulations contain inactive CPS of the pneumococcus, and the valency represents how many 
serotypes of pneumococcus the vaccine incorporates. There are three types of vaccines for 
pneumococcus in New Zealand, Pneumovax 23®, Prevenar-13® and Synflorix®. These 
vaccines all contain a mixture of inactive pneumococcus CPS. However, they differ in the 
number of serotypes in the vaccine. 
The pneumococcus vaccination programme has achieved great rates of reduction in invasive 
pneumococcal disease (56,57) by preventing host-to-host spread via reduced shedding (58). 
With the reduction seen in the invasive pneumococcal disease, it was postulated that we would 
observe a similar drop in the incidence and prevalence of acute otitis media with the uptake of 
vaccination (59). This hypothesis was supported by a study that reported a 20% decline in OM 
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hospitalisations in children less than six years between the last year of PCV7 use (2010: 1,631 
per 100,000 person-years) and the last year of PHiD-CV use before the switch to PCV13 (2013: 
1,303 per 100,000 person-years) (57). However, this study was primarily assessing 
hospitalisations due to invasive pneumococcal disease and all-cause pneumonia, and the AOM 
findings were secondary. Studies explicitly looking at AOM have shown no change in 
incidence or prevalence (4). Despite pneumococcal vaccination covering up to 80% of all 
known pneumococcal strains, and showing a significant reduction in vaccine-associated 
pneumococcus induced AOM, the vaccination against pneumococcus fails to demonstrate a 
reduction in overall all-cause AOM (60). The lack of reduction in all-cause AOM has been 
attributed to an increase in non-vaccinated strains and other pathogens (2). More recently, 
Palmu et al. have found a statistical reduction in the rate of tympanostomy tube insertion 
following pneumococcal vaccination, however, the effect size is small (3.6% 0.7-6.5%) and 
clinically insignificant (61).  
In New Zealand, Best et al. have examined the microbiology of the middle ear effusion in otitis 
media comparing a cohort of children receiving the 7-valent S. pneumoniae conjugate vaccine 
(PCV7) with a cohort of children that received the 10-valent pneumococcal vaccine (PHiD-
CV10) (62). The authors have found no difference in the change of composition of 
otopathogens in the nasopharynx or the middle ear effusion in these children with established 
ear disease.  
iii. H. influenzae and vaccination 
Vaccination for H. influenzae type B has significantly reduced severe life-threatening 
infections such as epiglottitis and meningitis. Due to the lack of capsular protein in NTHi, 
vaccination development against NTHi is more challenging (63). Furthermore, the pattern of 
infection and spread is different, with NTHi demonstrating direct mucosal infection in AOM 
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as opposed to haematogenous spread in H. influenzae type B in meningitis. Thus vaccine 
development for NTHi needed to utilise different immune pathways to prevent the mucosal 
infection effectively (63).  
Synflorix® is pneumococcal CPS conjugated to a recombinant non-lipidated form of the H. 
influenzae protein D. Protein D is a virulence conferring surface protein of H. influenzae and 
is well preserved across strains (63).  Vaccination against this protein has the potential to 
protect against AOM caused by NTHi. In a double-blind, randomised controlled trial enrolling 
nearly 5,000 infants, the 11-valent protein D-conjugated predecessor of Synflorix® showed 
significant efficacy against AOM caused by pneumococcal serotypes included in the vaccine 
(57.6%, 95% confidence interval [CI]: 41.4–69.3) and against AOM due to NTHi (35.3%, 1.8–
57.4), which translated into a significant protective effect on the overall AOM burden (33.6%, 
20.8–44.3) (64). This translated cross-reactivity serves as a proof of concept in the feasibility 
of vaccinating against NTHi. There are multiple potential surface markers of the NTHi 
identified as a possible candidate for vaccine development and are each at various stages of 
clinical trials (63). Unfortunately, none are currently available for the population.  
e. Treatment of otitis media in children 
Management of childhood acute otitis media has three primary considerations: management of 
the acute infection/inflammation, management of the middle ear effusion and associated 
hearing loss, and the prevention of recurrent episodes.  
Antibiotic prescriptions are associated with AOM presentations (6). However, the natural 
history of AOM suggests that conservative management alone, for individuals without red flag 
symptoms, will eventuate in the resolution of symptoms in up to 80% of the children (1,20,32). 
Additionally, the initial withholding of antibiotics does not appear to correlate with an increase 
in suppurative complications from otitis media (65), and there is mounting evidence against 
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routine antibiotic use (5). Therefore, the conservative and expectant approach is the most 
suitable acute management strategy for children aged over two (66). Nonetheless, antibiotics 
are indicated for children whose symptoms were worsening or without improvement after 48-
72 hours (47). 
Management of the acute inflammation in AOM involves the use of analgesics to relieve the 
discomfort and fever for these children. While the aetiology of acute otitis media involves the 
mucosal congestion and blockage of the Eustachian tube, studies investigating the use of 
antihistamines and decongestants found no clinically significant benefit (67). 
The management of the middle ear effusion associated with acute otitis media is primarily 
conservative (1,65). The natural history of the effusion often correlates to the episodes of acute 
inflammation. During the acute inflammatory phase, the exudate often is purulent, but with the 
resolution of the inflammatory phase, the effusion turns serous and gradually dissipates over 
time (47). Antibiotic use has shown some benefit in reducing abnormal tympanometry in weeks 
2-4 but makes no difference in tympanometry results at 3months (66). Although surgical 
management with myringotomy accelerates the return of hearing by draining the middle ear 
effusion, hearing benefits often regress due to the healing of the myringotomy. The short-
lasting nature of myringotomy can be mitigated by the insertion of a tympanostomy tube but 
at increased risk of persisting perforation of the tympanic membrane (29,68). 
For preventing relapses of acute otitis media, clinicians have used a protracted course of 
antibiotics. Although individuals demonstrate a mild reduction in the frequency of AOM while 
on the prolonged course, there is no conferred long-lasting benefit once the antibiotics stop 
(65,66). Therefore, this method is seldomly used due to the risk of antibiotic side effects and 
the rise of antibiotic-resistant bacteria. 
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Surgical treatment (with insertion of a tympanostomy tube) for recurrent acute otitis media 
(rAOM) remains a topic of controversy due to the lack of evidence (47). Evidence suggests 
two fewer episodes of AOM per child-year with the insertion of tympanostomy tubes (29,68). 
Despite the mild reduction in AOM episodes, tympanostomy tubes may be indicated for rAOM 
due to the benefits in reducing the duration of hearing deterioration, the discomfort of each 
AOM episode, and therefore, improving the disease-specific quality of life. Furthermore, 
children with tympanostomy tubes will be able to utilise topical antibiotics instead of systemic 
dosing, thereby reducing the side-effect profile. 
Whilst the insertion of a tympanostomy tube for recurrent acute otitis media is controversial, 
its role in the treatment in OME is better established (22). Likewise, surgical adenoidectomy 
demonstrates a minimal reduction in episodes of rAOM. Its primary role is in the prevention 
of further tympanostomy tube insertion for children with OME (20). 
f. Probiotics 
i. Definition of probiotics 
Etymologically, probiotics meant ‘for life’, and over time this terminology had changed from 
initially applying to a substance produced by one microorganism that promoted the growth of 
another; to substances that promote the balance of the microorganism in a given niche. It is not 
until recently that the term “probiotics” is formally defined by the World Health Organisation 
(WHO) as a live microorganism that confers a health benefit to the host when consumed in 
adequate amounts (69). Therefore, in its strictest terms, probiotics are consumed as a live 
microorganism that confers benefits to the host.  
Prebiotics are substances that are not hydrolysed nor absorbed in the gastrointestinal tract after 
host ingestion. Therefore, the compounds remain available as substrates for probiotic 
organisms and promote their growth and activity. The most commonly used prebiotics at 
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present is non-digestible fructo-oligosaccharides. The combination of a probiotic and prebiotic 
formulation is termed a conbiotic or symbiotic (70). 
The list of probiotic microorganisms is long, and its activity varies widely. The most common 
species of probiotics are lactobacillus and Bifidobacterium. Desirable probiotics have several 
qualities that are common amongst strains; these are i) ability to resist acid and bile if for oral 
administration; ii) ability to adhere to the mucosa especially if the competitive exclusion of 
pathogen or prevention of pathogen adherence and colonisation; iii) antimicrobial activity to 
pathogenic species (71).  
ii. Probiotics in preventative medicine 
There is an increasing number of publications that claim a beneficial effect on human health 
from the consumption of probiotics. Most commonly reported, are the health benefits of 
consuming probiotics on the gastrointestinal tract. However, other literature linking probiotics 
with reduced cholesterol and lower rates of cancer have been reported (70). The gradual 
accumulation of literature over time has substantiated the use of probiotics in diarrhoeal disease 
in infants, the prevention and treatment of antibiotics related diarrhoea (72) and improvement 
in gastro-intestinal lactose metabolism (73). Its use in other conditions is less well studied, and 
its effects are less established. 
Diarrhoeal disease is common amongst all ages, with an extended list of causes. Nonetheless, 
the acute infective cause remains the most common. Disturbances in the gastro-intestinal flora 
either from inoculation from the food ingested or the use of antibiotics can often lead to upset 
(72). Probiotics that mimic the organisms of healthy gut flora and have been demonstrated to 
be able to maintain, and in some instances restore the microbial balance. Probiotics taken 
preventatively have been documented to reduce the incidence and the severity of antibiotic-
associated gastrointestinal upset, however, the optimal dosing regime is still controversial (70). 
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Probiotics for the use of lactose intolerance aims to compensate for the genetic deficiency of 
beta-galactosidase deficiency. Although the actual in vivo effect of Bifidobacterium animalis 
is not fully understood, it is postulated that it has contributory effects from i) modifying gut 
pH, ii) expressing beta-galactosidase and iii) positively influencing the intestinal function or 
colonic microbiota (73).  
Conversely, there are disease processes in which probiotics have been proven to be ineffective, 
including acute pancreatitis (74) and Crohn's disease (75). Furthermore, although most of the 
probiotics are benign non-pathogenic species of microorganisms that are well-tolerated by all 
age groups, caution has been advised for use in severely immunocompromised populations. 
iii. Mechanism of action of probiotics 
There are multiple mechanisms in which a probiotic can exert its effect in suppressing 
pathogenic species. Although some mechanisms are unique to a particular probiotic organism, 
it is also accepted that some probiotics exert their effect through a multitude of the following 
mechanisms. Nonetheless, the major drawback in current literature, is that the proposed 
mechanism of action is based upon in vitro and in vivo gastrointestinal studies. Therefore, it 
remains uncertain whether the same mechanisms are replicable in the nasopharynx for 
probiotic use in acute otitis media.  
Pathogenic species often flourish in an environment where the pH is increased, which provide 
a convenient target for probiotic species to make the environment hostile (71). Probiotics alter 
the surrounding environment’s pH by metabolic by-products of lactic and other organic acids. 
It is however noted that although the organic acids make the environment unfavourable, that 
alone will not eradicate the pathogenic species (76). 
Nutrient competition is another mechanism for the probiotic organism to limit the overgrowth 
of the pathogenic species. Substrates for metabolism are a limited resource, and therefore by 
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inoculating the niche with probiotic species, direct competition for the limited resource will 
reduce the colony count of the pathogenic species (77). 
Mucosal barrier function enhancement is observed with certain probiotic organisms (71). The 
enhancement is mediated through the activation of toll-like epithelial receptors which in turn 
trigger the release of mucosal protective interleukins (78). These interleukins promote cellular 
regeneration, in conjunction with a reduction in tumour necrosis factor-alpha mediated cellular 
apoptosis. This then limits epithelial breakdown which retards the invasive infective process. 
An alternate pathway in reinforcing the mucosal barrier is carried through the protein kinase C 
pathway, reinforcing epithelial tight-junction integrity. 
Immunomodulation has been one of the better-studied and documented physiological changes 
associated with probiotics. There have been observable alterations to both the innate and 
adaptive immune systems (79). In a respiratory study, the use of oral probiotics induced the 
production and infiltration of CD4+ and CD8+ cells, upregulating the innate response in 
defence against pathogenic species. Natural killer cells were upregulated in another study 
whilst participants were on oral probiotics (80). 
Furthermore, modulation of mucosal inflammation is achievable by probiotics, and likely plays 
a role in the beneficial effects of probiotics. However, the evidence behind this is based on 
studies on inflammatory bowel conditions. Through the administration of probiotics, alteration 
of the T helper lymphocyte-mediated inflammatory response can be down-regulated, followed 
by decreased pro-inflammatory cytokines and resulting in less epithelial damage and 
subsequent opportunistic pathogenic invasion (81). 
Bacteriocins are protein antibiotics produced by certain bacteria that are toxic to other bacteria 
in their near vicinity (82). Their production is not universal and is colony dependent, in part 
with the interplay of the environment. These compounds are, however, naturally occurring and 
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are essential in ecological development and signalling between different strains. Bacteriocins 
are produced intracellularly and become active in the local environment in two ways; i) cell 
lysis and ii) active excretion.  Bacteriocins vary in size and mechanism of action. They also 
vary from narrowly targeting against phylogenetically similar strains to exhibiting broad non-
discriminatory effects. Once in the environment, bacteriocins work in a range of ways from 
targeting iron and other micro-nutrient receptors to immunomodulation, resulting in inhibition 
of competing organisms (83). 
iv. Bacteriocin like inhibitory substances - BLIS  
Bacteriocin like inhibitory substances (BLIS) is a term given to small peptide antibiotics that 
exhibit the same inter- and intra-species signalling and ecological significance as their larger 
counterpart bacteriocin. Unfortunately, due to their small size and low titre, it is often only 
partly purified and therefore, difficult to characterise (82). Bacteriocin and BLIS were 
gradually realised to be more widespread than initially thought, through work on genome 
sequencing. Escherichia coli were the first of the species identified to have bacteriocin activity. 
More recently species of Streptococcus, Bifidobacterium, Lactobacillus, Enterobacteria and 
Archaea have also been shown to produce bacteriocins or BLIS. (83). 
Streptococcus is one of the most diverse families of bacteria, various species are utilised in the 
food industry, while most are normal commensal organisms, some species are opportunistic 
pathogens (82). Many of the species within this family produce bacteriocin mainly in the 
lantibiotic class (a group of proteins that is post-translationally modified containing atypical 
amino acids, such as lanthionine residues) (84). S. salivarius is an oral commensal organism 
and is also one of the bacteriocin-producing species. Several strains of the S. salivarius 
harbours large plasmids for bacteriocin and BLIS production (82,85). S. salivarius is also a 
species that has low virulence and pathogenicity.  These ideal characteristics with the prolific 
Tzu Yu Chen MMedSc 2022556 
24 
 
bacteriocin producing activity make S. salivarius a promising candidate for probiotics for the 
upper aerodigestive tract.  
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CHAPTER 2 - RESEARCH AIMS 
a. Introduction 
The previous chapter has established the burden of disease for AOM in childhood and the lack 
of universal preventative measures. Probiotics are an appealing option for AOM prophylaxis 
and have been established in their safety and efficacy in its use in gastro-intestinal ailments. 
However, its use and role in AOM remain poorly understood and undefined. This thesis aims 
to delineate the probiotics’ potential role for use in otitis media-prone children.  
b. Previous student Dr Hendrickx thesis summary 
Previous Master’s student Dr Hendrickx has instigated some initial research into the feasibility 
of probiotics as a preventative agent for AOM. The research proposed to establish the 
tolerability and the plausibility to colonise the nasopharynx (86). The thesis recruited 16 
children (age 1 to 14 years) that were on the waitlist for tympanostomy tube placement for 
either rAOM or OME. Nasopharyngeal swabs were taken at recruitment, followed by a course 
of oral antibiotics (Co-Amoxiclav for 2 to 5 days) and then trans-nasal probiotics (S. salivarius 
K12 were administered for 4 to 9 days). Follow up nasopharyngeal swabs were taken at the 
time of surgery, and a tolerability questionnaire was filled out. The result showed 14 out of 16 
completed the study. Tolerability was good with 12 out of 14 reported good to excellent 
tolerability. Adverse events were reported in 3 participants out of the 14, 2 reported sneezing, 
1 with headache and 1 with cough (1 participant had 2 symptoms). The colonisation data was 
unavailable at the time of her thesis publication. However, personal communication suggested 
7 of the individuals had clear pre- and post-probiotic swab samples for analysis (despite 14 had 
completed the trial, some samples were mixed on arrival to the lab and therefore unidentifiable). 
All 7 of these individuals had no S. salivarius pre-probiotics, and all had at least one post-
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probiotic swab with S. salivarius K12 and suggested a 100% colonisation rate with the nasal 
formulation. 
This initial study had limited participants and although the participants were all awaiting 
elective tympanostomy tube placement, their age variation and indication for surgery were 
significant. The poor follow up rates of 7 identifiable pre and post swabs could reduce the 
colonisation rate to 50%. The heterogenous administration of both antibiotics and probiotics 
also poses potential confounding in the ability to colonise. However, the foundation work has 
established the good tolerability of the probiotics via the trans-nasal route. 
c. Masters research aims 
This thesis aims to establish the role of probiotics in the prevention of AOM in children by: 
 Determining the available literature and the efficacy of probiotics as a preventative 
measure. 
 Determine the characteristic of probiotics and the route of administration to facilitate 
colonisation. 
 Determine the ability of probiotics to inhibit the growth of otopathogens.  
 Determine the feasibility of colonisation the nasopharynx. 
 Determine the tolerability of different routes of administration.  
 
d. Thesis plan 
To determine the available literature this thesis will conduct a literature review and meta-
analysis on the use of probiotics as a preventative measure for children with recurrent AOM. 
The literature review will also encompass the characteristics of probiotics and the route of 
administration for AOM prevention. 
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To establish the antagonistic effects on the growth of known otopathogen the thesis will 
examine the in vitro inhibition by probiotic species.   
To establish the rate of colonisation of the nasopharynx by probiotics, this thesis plan to 
administer probiotics orally and trans-nasally. And, secondarily compare the tolerability of 
each route. 
e. Hypothesis 
This thesis postulate that there is no available convincing literature for the routine use of 
probiotics as AOM preventative measure.  
The inhibition profile of any probiotic is likely non-universal especially in light of the diverse 
range of otopathogen profiles.  
The colonisation of the nasopharynx will be better achieved with trans-nasal administration. 
Whilst tolerability will be higher with oral administration. 
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CHAPTER 3 – LITERATURE REVIEW  
(This chapter was published in the peer-reviewed journal Acta Paediatrica: Article DOI: 
10.1111/apa.15368; a copy of the article is attached in the Appendix section: Appendix 1) 
a. Introduction 
Acute otitis media is the most common bacterial infection in children for which parents seek 
medical advice (1). AOM commonly presents with fever, ear pain, and hearing impairment. 
Recurrent episodes of acute infection are common and, if untreated, can lead to complicated 
diseases, such as mastoiditis, sepsis, and intracranial abscess, resulting in significant morbidity 
(7,87). Cumulative periods of hearing loss can further lead to reduced language and learning 
development and affects the long term ability of the individual to build relationships (1,87,88). 
Common otopathogens include S. pneumoniae, NTHi, and M. catarrhalis (2,3). Colonisation 
with these organisms at a young age is associated with an increased risk of developing AOM 
in young children (1). Despite, the development of vaccination against strains of S. pneumoniae 
and NTHi, there has been little impact on the overall prevalence of otitis media. The lack of 
decreased prevalence is primarily accounted for by an increased presentation of non-vaccinated 
strains (2,4). 
Frequent and inappropriate use of antibiotics is associated with increasing antimicrobial 
resistance and facilitates colonisation with resistant strains of pathogenic species (5,6). Thus, 
in light of the prevalence and the considerable burden of this disease in the community, new 
strategies for preventing recurrent AOM are needed.  
i. Potential preventative role of probiotics in otitis media 
Previous research focusing on gastrointestinal illnesses has shown the benefits of probiotics on 
acute gastroenteritis and antibiotic-associated diarrhoea in children (89). Furthermore, benefits 
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have been seen in urogenital tract infections (90), hypersensitive conditions (91), necrotising 
enterocolitis in preterm infants (92) and irritable bowel syndrome (70). There are several 
proposed mechanisms in which the probiotic may confer its benefit and there were covered in 
the previous chapter. These proposed mechanisms may be strain-specific, and different 
probiotic strains likely have different mechanisms of effect.  
The nasopharyngeal flora of some individuals includes non-pathogenic commensal organisms 
that produce bacteriocin-like inhibitory substances and suppresses the growth of AOM oto-
pathogens in vitro (85). It is well established that nasopharyngeal flora is directly involved in 
the pathogenesis of AOM. Such that colonisation of the nasopharynx with an otopathogen 
predispose an individual to a middle ear infection (19). This theory provides a possible 
underpinning for the use of probiotics in the prevention of AOM. The colonisation of the 
nasopharynx with non-pathogenic species of BLIS producing organisms could interfere with 
otopathogens colonisation and be a viable means of preventing recurrent AOM. This literature 
review aims to present the current evidence on the use of probiotics to prevent AOM in children.  
b. Method 
i. Search methods and identification of studies 
Electronic databases MEDLINE, PubMed, EMBASE and Cochrane Library, were searched 
using keywords: probiotics, otitis media, ear infection, Lactobacillus rhamnosus, 
Streptococcus mitis, Streptococcus oralis, Streptococcus sanguis, S. salivarius, 
Bifidobacterium sp. The search terms were searched as MeSH terms as well as subject, terms 
with possible endings were denoted with “*” to expand the search. The result was limited to 
English language articles with human subjects. All articles up to January 2019 were screened 
for additional articles. All studies using probiotics as an intervention and otitis media as an 
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outcome measurement were included. All strains of probiotics were included, and any 
combination of the route of administration, dosage, and treatment duration.  
All full-text articles of all relevant studies were read and analysed. Meta-analyses and systemic 
reviews were screened to identify potential original papers. The articles have been 
independently reviewed to evaluate the merits and biases. All papers were discussed by all 
study authors. Disagreements on the grading of particular elements of any paper were discussed 
until a consensus can be reached. Each paper was graded based on the GRADE system (93). 
For each study (whether observational or interventional) the inclusion and exclusion criteria, 
the methodology, the randomisation and allocation process and blinding status were evaluated. 
The completeness of outcome data, selective reporting of outcomes and conflict of interest 
from the authors that may have the potential to introduce significant bias were noted. Each 
study was given an overall grade as good, fair or poor. 
  

















Total number of articles excluded 
(n=82) 
Non probiotics  20 
Review article  28 
Systematic Review 2 
Lab based probiotic study 15 
Non-AOM  15 
Meeting Notes 2 
134 papers screened. Non relevant and duplicate studies (n=41) removed. 
Review articles are reviewed for additional resources but removed from 
analysis. Additional 2 studies identified from review articles 
Total number of articles reviewed 
13 
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ii. Proposed outcomes measures 
Two overall outcomes were assessed, the efficacy and the safety of the probiotics in AOM. 
This review focused on comparing a child with and without probiotics and the number of 
episodes of AOM. The reported adverse events were used to infer the safety profile of the 
probiotics.  
c. Results of the literature review  
We identified 13 original research papers, after exclusion for non-relevance, reviews or meta-
analyses. (EMBASE 38, PubMed 52, Medline 43, Cochrane 1; see figure 3-1). Table 3-1 
summarises the papers included in this review. Although there is high heterogeneity amongst 
the literature, the studies with a discernible incidence of AOM episodes and those without 
significant study design flaws were presented in a forest plot in figure 3-2. 
 
i. Role of probiotics in preventing otitis media in healthy infants 
Probiotics are most easily administered orally in infants, but this generally excludes breastfed 
babies from trials. Studies using the oral route usually gave probiotics as a supplement to infant 
formula. 
Figure 3-2: Forest plot comparing the incidence of AOM episodes in Probiotics 
versus Placebo/Control group. 
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Rautava et al. included eighty-one healthy infants and newborns requiring formula before the 
age of 2 months, randomising them to daily milk supplemented with probiotics (L. rhamnosus 
GG, B. lactis Bb-12) or placebo, until the age of one year (94). The primary endpoint of this 
study was the incidence of early respiratory infections, including AOM, as diagnosed by a 
doctor. The incidence of AOM during the first 7 months of life and rAOM during the first 12 
months of life was significantly reduced in children in the probiotic group (Incidence of AOM: 
probiotic 22% vs placebo 50%, p=0.014). There was a reduction in the proportion of children 
with recurrent AOM, but this did not reach statistical significance (incidence of rAOM: 
probiotic 13% vs placebo 25%, p=0.183). 
Taipale et al. administered  B. animalis subsp. lactis BB-12 and xylitol via a pacifier to 109 
healthy newborns until the age of 8 months, allowing the inclusion of breastfed infants (89). In 
this randomised, double-blind, placebo-controlled trial, the primary outcome measures 
included the cumulative incidence of doctor-diagnosed AOM. They found no differences 
between the incidence of AOM in the probiotic group, compared to the placebo group 
(Incidence of AOM: probiotic 26% vs placebo 17%, p=0.455). However, the trial may have 
been confounded as the authors recovered BB-12 in 17% (6 of the 35 controls that completed 
the trial) of infants in the control group, which might be explained by maternal consumption 
of products containing BB-12. 
ii. Role of probiotics in preventing otitis media in healthy children 
Several trials have focussed on interventions in younger children, where the incidence of AOM 
and rAOM is highest. Hatakka et al. examined whether giving milk supplemented with L. 
rhamnosus GG or placebo to healthy children aged 1-6 years attending day-care, affected the 
rate of respiratory and gastrointestinal infections (95). The intervention lasted for 7 months 
during the winter, and respiratory infections were identified by daily symptom diaries 
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completed by parents over this period. AOM was included only if a doctor confirmed it. While 
there was a relative reduction of 17% in the number of children suffering from respiratory 
infections with complications, there was no overall reduction in the rates of AOM (age-adjusted 
odds ratio 0.78, 95% confidence interval 0.53 to 1.14). One possible explanation for the lack 
of demonstrable benefit was that Lactobacillus GG is a widely consumed probiotic in this 
population, and it was isolated from 15% of the children in the placebo group. 
Cohen et al. (96), studied the effects of a combination of probiotics and prebiotics in healthy 
formula-fed children aged 7 to 13 months with a high risk of AOM (day-care attendance and/or 
previous AOM). Their diagnostic criteria for AOM included the Paradise algorithm for acute 
suppurative otitis media (otorrhoea or effusion plus marked redness or marked bulging or 
moderate redness and bulging). Supplementing NAN 3™ follow-up formula with probiotics 
(S. thermophilus, S. salivarius, L. rhamnosus) and prebiotics (Raftilose/Raftiline) did not 
reduce the incidence of AOM or rAOM in infants when administered over 12 months 
(Incidence of AOM: probiotic 71% vs placebo 71%, p=0.8) (Incidence of rAOM: probiotic 
30.4% vs 30.4%, p=0.889). Although the authors collected information on medical events 
between visits, not all AOM episodes were seen by the authors, and this could have led to the 
under-reporting of episodes.  
iii. Role of probiotics in preventing otitis media in otitis media-prone 
children 
Otitis media-prone children are defined as having had at least four episodes of AOM during 
the preceding 12 months or at least three episodes in the last 6 months. They make an ideal 
group for studying the primary outcome, given the predisposition of these children to further 
episodes of AOM. However, the incidence of AOM reduces as children age, making 
longitudinal observational studies less than optimal for assessing the role of probiotics.  
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Roos et al. examined the effect of a nasal spray containing S. sanguis, S. mitis and S. oralis or 
placebo on the incidence of recurrent AOM in otitis-prone children (97). Otitis media-prone 
children were recruited, and clinical evaluations were done by three ears, nose and throat (ENT) 
specialists. Children were randomised to receive nasal spray with either probiotics or a placebo. 
A course of phenoxymethylpenicillin (penicillin-allergic children were excluded) was given 
before the probiotics. The probiotic nasal spray was then administered for 10 days, and after 
day 60, another 10 days of nasal spray were given. The incidence of rAOM during the 3-month 
follow-up period was reviewed, demonstrating a reduction in the probiotic group; more 
children in this group were cured (having normal tympanic membrane at all follow-up visits) 
after treatment (Recurrence of AOM: probiotic 40% vs placebo 51%, p=0.04) (Cured: probiotic 
42% vs placebo 22%, p=0.02). 
Hatakka et al. conducted a randomised, double-blind, placebo-controlled trial evaluating the 
effect of giving oral probiotics in an otitis-prone population (98). Children were given a 
probiotic (containing L. rhamnosus GG, L. rhamnosus LC705, B. breve 99 and P. 
freudenreichii JS) or placebo capsule daily for 6 months. The primary outcome measures were 
the occurrence and duration of AOM episodes, as diagnosed by a senior resident in 
otolaryngology. There was no statistically significant difference in the recurrence of AOM in 
the treatment group compared to the placebo group (Occurrence of AOM: probiotic 72% vs 
placebo 65%, p>0.05); (Recurrence of AOM: probiotic 18% vs placebo 17%, p>0.05). 
Marchisio and colleagues (99), randomised 100 otitis-prone children aged 1-5 years to receive 
nasal spray containing 24SMB S. salivarius or placebo. Over the 6 months study period, the 
authors found that 15 out of 50 children had no AOM versus 7 out of 47 in the placebo group 
(p=0.076). In a subgroup analysis looking at successful colonisation of S. salivarius 24SMB, 
children who became colonised with the probiotic strain had lower rates of AOM compared to 
non-colonisers (42.8 vs 13.6 %; p = 0.03). 
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iv. Oral versus trans-nasal delivery of probiotics and AOM 
Of the 13 studies included, 9 groups of authors chose to administer the probiotics via the oral 
route, in the form of supplemented formula milk, using lozenges/tablets, or powder given by 
mouth or fortified milk (89,94–96,98,100–103). The 4 remaining groups utilised the trans-nasal 
route, in the form of a nasal spray (97,99,104,105). No trials have directly compared oral versus 
trans-nasal administration of probiotics. Also, very few trials have systematically looked at 
mucosal colonisation before and after probiotics, to determine the role of colonisation in any 
treatment effects.  
Of the studies using oral probiotics, 3 (33%, 3/9) demonstrated a statistically significant impact 
on the incidence of AOM (94,101,102). In a small pilot study( n=22), Di Pierro et al. found 
children between 3-9 years of age, when given a daily nighttime dose of S. salivarius K12 for 
90 days, had significantly fewer AOM episodes during follow-up, compared to the preceding 
year (0.23 vs 0.4; P<0.01) (101). The same author led a larger randomised unblinded and 
uncontrolled trial in 2016, giving children around the age of 3 a 180-day course of S. salivarius 
K12. When compared at 6-months follow up, the group that received probiotics had 
significantly fewer bouts of AOM (40.1% vs80.2%; p<0.01) (102). However, these studies had 
significant methodological issues, including unblinded interventions, a lack of age-matched 
controls and ill-defined study endpoints. Rautava and his colleagues were the only groups to 
yield statistically significant results in reducing AOM, but it failed to reach significance for 
rAOM (94). The 6 other studies giving oral probiotics, inclusive of otitis-prone and healthy 
children, found no benefit in reducing the incidence of AOM.  
Four trials investigated the impact of probiotics administered via trans-nasal spray, with 2 (50%, 
2/4) finding a statistically significant reduction in AOM (97,104). Roos et al. recruited 108 
children between 6 months to 6 years of age in a randomised, blinded, placebo-controlled trial 
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using Streptococcus. mitis, Streptococcus. oralis, and Streptococcus. sanguis. The group found 
a reduction in the incidence of AOM during 3 months follow up (22/53 vs 12/55 had no AOM 
episodes; p=0.02) (97).  
Tarantino et al. demonstrated in a non-blinded retrospective observational study that children 
given S. salivarius  24SMB and S. oralis  89a nasal spray had significantly less upper 
respiratory tract infection than the preceding year; otitis media is within this conglomerate 
diagnosis of upper respiratory tract infections (5.98 episodes vs 2.43 episodes p<0.0001) (104). 
The natural trend of decreasing incidence of AOM with increasing age makes interpretation of 
this study difficult. Combining all types of upper respiratory tract infections as an outcome 
measure makes it difficult to discern the effect of probiotics on AOM episodes.  
v. Reported adverse effects of probiotics in literature 
Out of the thirteen articles included in this literature review, twelve had provided data regarding 
adverse events. No adverse events were reported in any of the treatment groups, in 7 of 12 
studies. In the remaining 5 studies, 3 report adverse events of minor clinical severity including 
constipation, burning, longstanding cough and rhinitis (96,99,105). In one study, two infants 
withdrew because of a gastrointestinal complaint (89). One study reports several children 
experiencing side effects without specifying the side effect (97). No serious adverse events 
were observed in any of the included studies. 
d. Discussion 
Otitis media is one of the most common infections in young children and for children to be 
prescribed broad-spectrum antibiotics. While probiotics may be an attractive preventative 
strategy for some infections, this review found only limited data supporting their role in the 
prevention of otitis media. Most of the studies identified had significant methodological 
limitations, making it difficult to evaluate the utility of probiotics in this setting. Administration 
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of probiotics in children appears to have a good safety profile in general, with no reports of 
severe or systematic adverse events. 
The diagnosis of AOM is often challenging to make with precision, as tympanic membranes 
may appear red in a febrile child in the absence of AOM, especially in young children (47). 
The lack of a clear definition of AOM and variability in determining the primary outcomes was 
a common concern in many of the studies in this review. Most of the trials used either parental 
reporting of AOM or included them if they were “doctor determined”, with this term not 
otherwise specified. Few studies included evaluation by an Ear Nose and Throat specialist. If 
over-diagnosis of AOM occurs, it is likely to reduce any impact of interventions, which is 
critical in small trials, with limited statistical power. Any real effect of a probiotic intervention 
may not be identified. In un-blinded trials, the influence of diagnostic uncertainty around AOM 
is likely to be significant enough to make the trial outcomes unreliable. Future probiotic trials 
should include clearly defined endpoints for AOM and would be preferable to have evaluations 
done by clinicians skilled in the diagnosis of AOM.  
The pathophysiology of AOM suggests that an ideal probiotic would establish itself in the flora 
of the nasopharynx. Interfering with pathogens migration from the nasopharynx to the middle 
ear in the process of causing ear disease (106). However, most of the studies in this review 
administer probiotics orally, perhaps because the administration of nasal sprays can be 
challenging in small children (19). The extent to which this leads to colonisation in the 
nasopharynx is unknown. Some studies used pre-treatments before starting with probiotics, 
such as a chlorhexidine mouthwash or antibiotics, which may affect the nasopharyngeal 
microbiota, to promote colonisation by probiotics. However, there is little data on the impact 
of sterilisation procedures on the rates of eradication of microflora and colonisation of 
microflora (107).  
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Only one of the studies included information on colonisation as part of their study, and on sub-
group analysis, it would appear that colonisation has a contribution to the efficacy of the 
probiotic (99). If the mechanism of any probiotic effect is indeed dependent on the colonisation 
of the host, then this information is essential in defining the reasons for success or in fact failure 
of any particular trial.  
The age of the participating children ranged from 2 months to 12 years old in the papers of this 
review. However, the risk of AOM varies significantly with age, with less than 2-year-olds 
being at most risk. The trials with the inclusion of the older children may be less likely to 
demonstrate an effect. Observational studies which compare the rates of AOM in children at 
different ages should be interpreted with caution, given the natural history of this disease is that 
incidence reduces with age.  Most of the trials were too small to allow the reporting of age-
stratified outcome data. Future research should use appropriate age-matched controls in all 
intervention studies to reduce the risk of time-related bias. In addition, the rapid changes that 
occur in the relative risks of AOM during infancy and early childhood meant consistency in 
the timing of interventions concerning the child’s age is essential.  
e. Limitations of the available literature  
The significant limitations of this review are the heterogeneity of the studies. Different 
probiotic strains were used across studies, some containing single strains (e.g. L. rhamnosus 
GG, B. breve 99, S. thermophilus, S. salivarius), others used a combination of strains 
(67,89,94,95,98,104,105,108). Given the mechanism of action of probiotics can be strain-
dependent, this could be an explanation for the inconsistent results. The duration of the study, 
administration route, study design, and outcome measures also differ significantly between the 
studies. These methodological differences make it very difficult to evaluate the overall impact 
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of probiotics as an intervention to prevent AOM or to make any recommendations about their 
use.  
f. Feasibility of probiotics for AOM prophylaxis 
The effectiveness of probiotics as prophylaxis against AOM has not been demonstrated. Were 
probiotics to be recommended for prophylaxis, there are several gaps in the current knowledge 
around the use of probiotics that would need to be addressed. The following section summarises 
some of these areas where more research is needed.  
i. The viability and stability of probiotics  
Probiotics are commercially available and have been demonstrated to be efficacious in some 
fields of preventative medicine (72). The development of probiotics commercially is a 
convoluted journey and requires reaching multiple targets (109). S. salivarius was pioneered 
as a probiotic species for the upper aerodigestive tract for it is low virulence and pathogenicity, 
meanwhile exhibiting high levels of megaplasmid transfer and BLIS production (110). During 
the development phase, the stability (the viability of the probiotic in the dosing format) and the 
shelf-life (the duration in which the probiotic remains viable) were studied (103). It has been 
demonstrated that in storage at 4°C, the stability is maintained for at least 6 months, while at 
25°C the CFU count drops from 1.7 x1010 to 5 x109. 
ii. Inhibition profile of the probiotics 
S. salivarius was initially selected as a probiotic choice for its strong inhibition of S. pyogenes 
a well-known pathogenic species of the oropharynx (111,112). However, over time, inhibition 
of more pathogenic species has been implicated. Whilst some of the inhibition is in vitro (113), 
newer studies have been replicating in vivo environments (114). 
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iii. Inhibition of otopathogens 
Otopathogens, S. pneumoniae, NTHi and M. catarrhalis inhibition by probiotic species have 
been implicated (97). There are some in vitro studies the implicate bactericidal effects of some 
strains of alpha haemolytic Streptococcus towards otopathogens, but the evidence is deficient 
(115). However, only models for in vivo inhibition of S. pneumoniae is available for S. 
salivarius (114). The available literature generally lacks data on the ability and mechanism of 
inhibition of the other otopathogens. There are no trials that demonstrate satisfactory inhibition 
of all otopathogens from single probiotic species, and hence further research into this is 
required. 
iv. Ability to colonise with probiotics 
Probiotics detection whilst an individual is taking probiotics is achievable, in previous 
gastrointestinal (116) and oral cavity studies (117). However, long-term colonisation data are 
lacking and likely improbable (117). Furthermore, attempted colonisation of the nasopharynx 
adds another layer of complexity to the difficulties experienced in the colonisation of the oral 
cavity and gastrointestinal tract, due to its anatomical location. Orally administered probiotics 
will have to reflux superiorly to reach the nasopharynx, with soft palate preventing such 
regurgitation. 
v. Duration of colonisation. 
The literature on the duration of colonisation of the nasopharynx for S. salivarius was scarce. 
Santagati and colleagues (118) did conduct a small (n=20) pilot study on the colonisation of S. 
salivarius 24SMB and found initially 95% had colonised immediately after treatment, 
deteriorating to 55% at 6 days after the last dose. Similarly, multiple oral cavity studies have 
shown a quick reduction in the probiotic species after completing the course (117,119,120). 
Therefore, long-term colonisation is unlikely. These studies also did not indicate whether the 
Tzu Yu Chen MMedSc 2022556 
42 
 
probiotics were actively secreting BLIS whilst colonised. Therefore, further research is needed 
to ascertain the feasibility of probiotics prophylaxis against AOM. 
vi. Role of antibiotic and antiseptic in the colonisation of probiotics 
The use of introductory antibiotics or antiseptic use prior to introducing probiotics is not well 
studied. The underlying theory was to attempt to decrease the number of pre-existing micro-
organisms in the niche to facilitate colonisation by the probiotic species. It is well known that 
both the normal flora and the probiotics S. salivarius are sensitive to antibiotic treatment 
(121,122). Therefore, inferring from the short colonisation period after cessation of probiotics 
and the sensitivities of the probiotics to antibiotics, antibiotic use after probiotics is likely to be 
detrimental to colonisation. The magnitude of the detrimental effect of this, however, will need 
further investigation.  
vii. The dose of probiotics for colonisation  
Probiotic products come in various types of preparations, pending their intended use. Only a 
few studies have been completed to determine the exact dosage required to colonise the 
intestine. However, suggested by a meta-analysis by Johnston et al., a dose of 5–40 billion 
CFU/day of Lactobacillus GG had the most promise in establishing colonisation and reducing 
antibiotic-associated diarrhoeal disease (123). Nonetheless, colonisation of the upper 
respiratory tract is different and encounters less loss from the ingested probiotics being exposed 
to stomach acid. Work by Burton et al have suggested that lower CFU is required to colonise 
the upper respiratory tract (122).  
viii. Safety profile and adverse effects 
The safety of probiotics S. salivarius have been extensively published (118,124), and in a 
normal immune-competent individual does not cause disease. However, this would need to be 
demonstrated for each probiotic being considered for clinical use.  
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ix. Route of administration and tolerability 
The route of administration is varied, depending on the niche that needs to be colonised. 
Nasopharyngeal colonisation is anatomically more challenging from oral dosing compared to 
trans-nasal dosing. Nonetheless, a direct comparison between the two routes has not been 
undertaken. The tolerability of S. salivarius is high in multiple previous studies (86,118). 
Likewise, the tolerability of oral versus nasal formulation has not been compared. 
x. Overall summary on the feasibility of probiotics 
S. salivarius is a safe and potential probiotic option for upper respiratory tract infections. It has 
excellent pharmacological stability and shelf-life. However, the evidence is lacking in the 
ability of S. salivarius to inhibit otopathogens and colonise the nasopharynx effectively. The 
optimal route of administration is also debatable and has not been established. The colonisation 
rate of the mucosa versus the adenoid pad is also not established. Likewise, the duration of 
probiotic colonisation remains uncertain. Whether established colonies of the probiotic in the 
nasopharynx will produce BLIS (as it does in vitro) is also unknown. The dosage for an optimal 
gastrointestinal ailment may have been established, but the optimal dose for nasopharyngeal 
colonisation also remains to be investigated.
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Table 3-1 Literature review summary  



















Inc: Children between 1-5yo with 
hx of rAOM, Exc: severe atopy, 
acquired or congenital 
immunodeficiency, craniofacial 
abnormality, obstructive adenoids, 
OSA, tympanostomy tube, chronic 
ruptured eardrum. 
Co-Amoxycillin-Clav 
80mg/kg/day in 3 doses for 10 
days followed by Streptococcus 
salivarius 24 SMB nasal spray 
twice per day for 5 days and 






Children were monitored 
throughout the 3 months 
and 3 months after for the 
number of AOM's. 
Secondarily 
nasopharyngeal swabs 
were taken to determine S. 
salivarius colonisation 
14.9% Children treated 
with probiotics had no 
AOM episode vs 30.0% 
in placebo. (p=0.076); 
73% children needed 
antibiotics in treated 
group vs 83% in placebo 
group (p=0.13); 25/50 
colonised after the first 
5-day course 28/50 was 
eventually colonised; 
13.6% of Colonised 
children had AOM vs 
42.8% in placebo 
(p=0.03); and 67.8% 
colonised children 
needed antibiotics vs 
95.5% in placebo 
(p=0.029) 
nasal spray >0.05 
* 
Fair 




43 (I=21 C=22) Children aged <3 yo; Exc: OME, 
immunodeficiency, valvular heart 
disease, wounds in the nose or 
mouth 
5 Strain (2x S sanguis, 2x S mitis, 
and S oralis) suspended in 5% 
skim milk and 0.9% Saline for 






Frequency of AOM, URI, 
otalgia, OME 
URI in AHS spray group 
49v66 in placebo 
p>0.05; AOM 44% 
v40% P>0.05; number 
of AOM episodes 11v9 
p>0.05; otalgia 
nasal spray >0.05 
* 
Good 
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80 (I=80 C=80 
previous year) 
Inc: 3-14yr, both gender, 
documented history of URI; Exc: 
severe allergic symptoms, 
congenital or acquired 
immunodeficiency, craniofacial 
abnormality, sleep apnoea, Down's 
Syndrome, chronic disease passive 
smoking, recent or current use of 
immunomodulant, steroids 
Streptococcus salivarius 24SMB 
and Streptococcus oralis 89a 
(Rinogermina nasal spray DMG 
Rome Italy) 2puffs/day for 7 days 
repeated for 3 months during 
autumn 
Same group of 
children 1-
year prior 
Primary: number of URI (2 
of the following: fever, 
mucopurulent rhinorrhoea, 
sore throat, cough, otalgia, 
mucopurulent secretions 
for 48 hours), number of 
days off school/work 
URI 2.75 vs 5.98 
episodes per 12 months 
(p<0.0001). Days off 
school reduced from 
2.8vs 4.5 days 
(P<0.0001) 




same group of 
children in the 
previous year 










Inc: Children between 6 months and 
6 years with AOM; Exc: penicillin 
allergy, serious underlying disease, 
immunological deficiency, valvular 
heart defect, major lesion in the 
mouth or nose, grommet in the ear 
or chronic otitis media 
Phenoxymethylpenicillin 
25mg/kg BD for 10 days (no 
AOM in 1 month) or Co-
Amoxycillin-Clav 20mg/kg BD 
for 10 days (AOM in the last 
month). Followed by nasal spray 
composed of 5 strains of Strep 
from healthy children. (2x 
Streptococcus sanguis, 2x 
Streptococcus mitis and 
Streptococcus oralis) 3 puffs each 








Occurrence of OM during 
the 3 month follow up 
period 
22/53 in the probiotic vs 
12/55 in the control 
group had no AOM's 
during the follow up 
p=0.02;  














Children aged 7-13 months, full-
term baby, >6kg, able to tolerate 
oral formula of 300ml/day; Exc: 
twins, children with chronic 
disease, allergy to cow’s milk 
protein, participating in another 
clinical study,  
Formula milk (NAN 3) with 
Streptococcus thermophilus NCC 
Streptococcus salivarius DSM, 
Lactobacillus rhamnosus LPR 




primary outcome measures 
the incidence of AOM in 
each group in the 12 
months,  
Number of episodes of 
AOM by Paradise 
criteria 160vs 161 
P=0.39; rAOM 
30.4%v30.4% p=0.889; 
LRI episodes 107vs121 
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P=0.625; Antibiotics use 
for AOM 242 vs 226 in 









Inc: children aged 1-6 yo enrolled in 
municipal daycare; Exc: allergy to 
cow’s milk, lactose intolerance, 
severe food allergy, and severe 
chronic diseases 
Lactobacillus rhamnosus GG 
milk (Gefilus Valio Riihimaki 
Finland), served three times a day 
for 5 days a week consuming at 
least 200mls, (compliance 60%). 






Number of days with 
respiratory and GI 
symptoms or days with any 
illness, absences from 
daycare centre because of 
illness, number of children 
with URI with 
complication (AOM or 
sinusitis) and LRI. Also, the 
correlation between the 
amount of milk consumed 
and the number of days 
with symptoms and a 
composite surrogate 
symptom score. 
Age adjusted days of 
illness 25vs 26p = 0.59; 
days of respiratory 
symptoms 21vs22 p= 
0.67; age-adjusted odds 
ratio of AOM episodes 
0.78 (0.53-1.14) p=0.19   
oral 
formulation 














Inc: Children between 10months 
and 6 yo with hx of RAOM. Exc: 
regular medication, chronic 
illnesses, Downs syndrome, lip or 
palatal cleft, OME, children 
scheduled for As or VTs. 
Daily Capsule containing 
Lactobacillus rhamnosus GG, 
Lactobacillus rhamnosus LC 
Bifidobacterium breve; 
Propionibacterium freudenreichii 
ssp shermanii JS (Valio Let 






Primarily the occurrence 
and duration of AOM's. 
Secondarily the frequency 
of pathogen carriage, 
recurrent URI, and the 
number of antibiotics 
treatments.  
Median number of AOM 
episode in probiotics 1 
vs 1 in placebo group 
p=n.s.; AOM duration 
5.6vs 6 days p=n.s.; >/= 
to 1 episode of AOM 
was 72% in probiotics vs 



















81 (I=38 C=43) Inc: need for infant formula before 
the age of 2months. Exc: babies 
with chronic disease 
Lactobacillus rhamnosus GG and 
Bifidobacterium lactis Bb-12 in 







Incidence of   respiratory 
infections, doctor-
diagnosed AOM and GI 
infections, by 7 months of 
age, antibiotics use or 
tympanostomy tube by 12 
months of age 
At 7months: Respiratory 
infections RR 0.89 
p=0.4; AOM RR 0.44 
p=0.014; GI infection 
RR 0.21 p=0.091; 
Antibiotics use RR 0 52 
p =0.015 @ 12 months: 
RI RR 0.51 p=0.022; 
AOM RR 0.50 p=0.183; 
Antibiotics use RR 0.41 














82 (I= 45 + 20 + 
17) 
Inc: Children 3-12 yo with consent 
Exc: <3 or >12 OSA, respiratory or 
systemic severe pathologies, 
asthma, healthy carrier of S 
pyogenes 
82 children were composed of 65 
with recent infection and 17 
without. Of the 65, 45 were 
enrolled to take Streptococcus 
salivarius BLIS K12. (Bactoblis) 
- Recurrent treated group; 
Remaining 20 of the recently 
symptomatic (recurrent non-
treated) together with the 17 
without recent infection (non-
recurrent and non-treated)  
Same group of 
children 1-
year prior 
Frequency of medical 
visits, the result of throat 
swab and otoscopic signs of 
otitis media and episodes of 
pharyngitis tonsillitis or 
AOM 
In children with history 
of recurrent tonsillitis 
and untreated with 
probiotics, the incidence 
of AOM is 0.117 vs 
0.054 episodes per child 
per month. In the treated 
group, the incidence is 
0.039 vs 0.020 episodes 
per child per month. 
Episodes of AOM 
during probiotics 0.033 
vs 0.055 episodes per 
child per month. 
oral 
formulation 




same group of 
children in the 
previous year 










109 (I=55 C54) Inc: willing patient family for the 
use of a pacifier, healthy child, and 
able to start receiving probiotics 
before 2 months; Exc: not 
documented 
Bifidobacterium animalis Subsp. 
Lactis BB12. Two tablets per day, 
dispensed by the baby sucking on 
the small pacifier (contains 
100mg xylitol) until 6-8 months 
Randomised 
to have xylitol 
only pacifier 
The occurrence of AOM, 
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of age then by a larger pacifier 
(contains 300mg xylitol).  




2015 Pilot study 22 Inc: children 3–9 yo having a recent 
history of rAOM and with unilateral 
or bilateral OME; Exc: severe 
underlying disease, immune 
deficiency, heart disease or 
congenital heart defects, sore 
mucosae, antibiotic use within the 
last month, and upper respiratory 
tract infection in the 10 days 
preceding the enrolment 
1 tablet of Streptococcus 
salivarius K12 (Bactoblis) was 
administered to each subject 
every night, just before sleep, for 
90days 
Same group of 
children 1-
year prior 





AOM incidence 0.23 vs 
0.4 episodes per month 
per child P<0.01. 
oral 
formulation 




same group of 
children in the 
previous year 










Inc: Children aged around 3yo 
about to start 1st year of 
kindergarten, All participants were 
free of streptococcal disease; Exc: 
immunocompromised, undergone 
tonsillectomy or 
adenotonsillectomy, history of 
rheumatic fever, bronchospasm, 
diagnosis of asthma or allergy, 
respiratory  or significant systemic 
disorder, concurrent 
pharmacological therapies to 
prevent recurrent respiratory 
infections, atopy, cleft palate, 
chronic ruptured eardrum, 
obstructive adenoids, craniofacial 
abnormalities, OSA or VTs 
Streptococcus salivarius tablets 
in the form of BLIS K12 
(Bactoblis) daily at night time for 
180 days. Then a small group of 
29 children from each group is 
followed for further 3 months 
111 children 






Side effects or symptoms of 
toxicity of BLIS K12; the 
efficacy of BLIS K 12 in 
the prevention of 
pharyngotonsillitis and 
scarlet fever; efficacy of 
BLIS K12 in reducing the 
occurrence of AOM 
At 6 months AOM seen 
in 40.1% of the treated 
vs 80.2% in the 
controlled P<0.01; At 
further 3 months AOM 














Summary of the literature review. I= Intervention group; C= Control group. The second last column denotes the studies that were compiled in the forest plot by "*"; reason for excluded study from forest plot provided. 
The last column denotes the assigned overall quality of the paper by the current author group. 
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CHAPTER 4 – S. SALIVARIUS VERSUS OTITIS MEDIA 
OTOPATHOGEN ISOLATES 
(This chapter was published in peer-reviewed journal Probiotics and Antimicrobial Proteins: 
Article DOI: 10.1007/s12602-020-09719-7; a PDF version of the article is attached in the 
Appendix section: Appendix 2) 
a. Introduction 
Acute otitis media (AOM) is the most common bacterial infection occurring in pre-school aged 
children (1,2). A proportion of children go on to develop recurrent AOM or persistent middle 
ear effusions, with a significant impact on the affected families (3,4). The three most common 
otopathogens in young children are S. pneumoniae, NTHi and M. catarrhalis (5,6). 
To date, vaccines have had only a modest impact on the incidence of AOM. There are 
increasing concerns regarding the overuse of antibiotics for the treatment of childhood AOM 
(7), along with concerns regarding antibiotic resistance as a consequence of high antibiotic 
consumption amongst children in New Zealand (8). Accordingly, alternative prevention and/or 
treatment options have been sought, including exploring a possible role for probiotics in the 
prevention of AOM (9–11). 
Although there are many postulated mechanisms by which a probiotic could prevent infection  
(12),  potentially the most effective of these is via the relatively-specific probiotic mediated 
bacteriocin interference with the growth of the potential pathogens at the site of colonisation.  
Bacteriocins are proteinaceous substances produced by bacteria that display inter- and intra-
species antagonism.  The widely-used probiotic bacterium, S. salivarius K12  (BLIS K12 ™ ) 
was originally isolated from the oral cavity of a healthy child and subsequently has been shown 
to produce the bacteriocins salivaricin A, salivaricin B and salivaricin MPS (13). It has been 
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suggested that bacteriocin-producing probiotics could potentially be used to prevent otitis 
media infections in children based on their demonstrable inhibition of otitis media pathogens 
in vitro (14).  
However, before the selection of a candidate anti-AOM probiotic for efficacy in clinical trials, 
it is essential to first evaluate their in vitro inhibitory capabilities against isolates of known 
AOM pathogens. 
b. Aim 
This study aimed to evaluate the inhibitory activity of BLIS produced by S. salivarius K12 
against known pathogenic species from otitis media isolates. 
c. Hypothesis 
S. salivarius BLIS will inhibit the growth of otopathogens.   
d. Method 
i. Source of oto-pathogenic species Isolates 
The isolates from the middle ear are obtained by a previous study comparing isolates from 
middle ear effusion of otitis media-prone children to the nasopharyngeal composition of non-
otitis media-prone children, conducted by Mills et al. (3). The middle ear effusion was obtained 
between May to November 2011 and January to December 2014 via tympanocentesis 
intraoperatively from otitis media prone children undergoing elective ventilation tube insertion. 
The swabs are obtained by sterile technique and then transported in STGG broth. The sample 
is promptly sent to the local medical laboratory (<4 hours), where the pathogenic organisms 
are identified and isolated. Middle ear effusions with multiple strains of pathogenic species 
generated multiple isolates. The isolates were then stored at minus 70 degrees Celsius, and not 
thawed until this study. Isolates obtained included: Haemophilus influenzae (HINF), S. 
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pneumonia (PNEU), M. catarrhalis (MCAT), Pseudomonas aeruginosa (PAER), 
Staphylococcus aureus (SAUR), S. pyogenes (STRA), Staphylococcus lugdunensis (SLUG), 
Alloiococcus otitidis (AOTI), Turicella otitidis (TOTI) and yeast (not Candida albicans) 
(YNCA).  
From the Otitis Media Infectious aetiology & Vaccination Impact (OMIVI) study a total of 441 
middle ear effusion samples were collected, 13 were lost or unable to be processed, giving 
results from a total of 428 middle ear samples.   
ii.  Preparation of the pathogen isolates 
The frozen isolates are removed from the minus-70 degrees Celsius storage and thawed to 
ambient room temperature (20 degrees Celsius). The isolates of H. influenzae were sub-
cultured onto the Haemophilus testing medium (HMT) agar [BD™; beef extract 2g, acid 
hydrolysate of casein 17.5g, starch 1.5g, agar 17g, yeast extract 5.0g, hematin 0.015g, 
nicotinamide adenine dinucleotide (NAD) 0.015g]. The other pathogen isolates were sub-
cultured onto the human blood calcium (hBaCa) agar [Columbia agar base 44g, calcium 
carbonate 0.1%, universal human blood, and distilled water]. H. influenzae was sub-cultured 
to the HMT agar due to the inability to culture the organism onto the hBaCa agar. Standard 
inoculation procedure with the streak-plate method onto the culture agar was used with heat 
sterilisation of wire of the inoculation hoop between samples (133).  
Inoculated agars were then incubated at 37 degrees Celsius and 5% carbon dioxide for 18 hours 
and interpreted for growth. Those who demonstrated no growth were further incubated and 
checked for growth at 24 hours intervals. Isolates were deemed non-viable after 6 days of no-
observable growth.  
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iii. Probiotic Streptococcus salivarius K12 
S. salivarius K12 (BLIS K12™) is a non-pathogenic probiotic developed by BLIS technologies 
Dunedin Ltd for its ability to produce bacteriocins (BLIS) naturally. The antibiogram, 
metabolic profile, and virulence determinants of the S. salivarius K12 have been studied and 
demonstrated by Burton and colleagues (122). Whilst the study by Tagg which demonstrated 
anti- S. pyogenes hinted at clinical efficacy at the prevention of palatine tonsillitis (111).  
iv. Deferred antagonism inhibition testing 
The ability to identify bacteriocin production by S. salivarius K12 was determined using the 
deferred antagonism test devised by Tagg and Bannister (113). In this test, the producer strain 
secretes the bacteriocin(s) onto the bacterial growth medium and following this various 
bacterial indicator strains are applied to this medium. If the bacteriocin inhibits the indicator 
strain, then regions of no growth are seen on the agar. Using this method, bacteria can be 
identified and classified by their ‘bacteriocin fingerprints’— also known as P-typing (113). 
To ensure this experiment have equitable BLIS production by S. salivarius K12 in the two 
different mediums (hBaCa agar and HTM) deferred antagonism was performed. (see sub-
section vi.) 
v. Preparation of the producer strip 
The BLIS producing species (S. salivarius K12) was inoculated with sterile cotton-tipped swab 
onto the human blood calcium agar (hBaCa) and the Haemophilus testing medium (HTM) agar, 
over a 1-cm strip (producer strip). The producer inoculated medium was then incubated at 37 
degrees Celsius and 5% carbon dioxide for 18 hours. This process enhances the proliferation 
of the S. salivarius strain and its production of BLIS to diffuse into the surrounding agar 
medium. The macroscopic colonies of the salivarius species were scraped off with a sterile 
cotton-tipped swab. Microscopic remnants were sterilized with chloroform vapour (by flipping 
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the medium upside down over chloroform-soaked filter paper) for 30-minutes. The medium 
was then aerated over 15 minutes to remove residual chloroform.  
vi. Validation of BLIS production 
To validate the production of BLIS from S. salivarius K12 in the hBaCa and the HMT agar, 
the producer strip was repeated in each of the agars and had indicator strips tested. The 
indicators are standardised I1-I9, listed below (134):  
I1: Micrococcus luteus strain T18 
I2: Streptococcus pyogenes strain FF22 
I3: Streptococcus constellatus strain T29 
I4: Streptococcus uberis strain T6 (ATCC27958) 
I5: Streptococcus pyogenes strain 7179 
I6: Lactococcus lactis (subsp. lactis) 
I7: Streptococcus pyogenes strain 71698 
I8: Streptococcus pyogenes strain W1 
I:9 Streptococcus equisimilis strain T148 
 
vii. Pathogen isolate suspension 
Todd-Hewitt broth (THB) [Bacto™; heart infusion 3.1g, neopetone 20g, dextrose 2g, sodium 
chloride 2g, disodium phosphate0.4g and sodium carbonate 2.5g] was prepared in a clean 
environment and autoclaved (120 degrees Celsius for 15 minutes) to ensure sterility. The THB 
was then cooled down to room temperature, to prevent the heat-kill of the otopathogen isolates. 
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The sub-cultured clonal pathogen isolates were then picked up by sterile cotton-tipped swabs 
and suspended in the 1ml aliquots of the THB.  
viii. Inoculation of the indicator strip 
The TBH suspended non-Haemophilus pathogenic species (indicator strip) are then transferred 
at a perpendicular angle to the producer strip onto the BLIS infused hBaCa agar 
unidirectionally. The NTHi are inoculated similarly onto BLIS infused HMT agar. These agar 
plates were then returned to the incubator at the same setting (37 degrees Celsius with 5% 
carbon dioxide for 18 hours). The isolates were separated by species. The plates were retrieved 
after incubation and read independently by two primary investigators, Tzu Yu Chen and 
Abigail Voss, with all discrepancies discussed and finalised. 
ix. Interpretation of results 
The results were interpreted by two of the primary investigators, Tzu Yu Chen and Abigail 
Voss. Any discrepancy in the result interpretation was discussed to reach a consensus. For this 
study, pathogenic inhibition was quantified based on the zone of inhibition. This is denoted as 
“-“, “+”, “++”, “+++”, and “++++”. If the indicator strain growth is across the producer strip 
without a break, then it is denoted as “-“ (that is the indicator strain is resistant to the BLIS 
produced by S. salivarius K12). If the indicator strip grows over the producer strip but 
demonstrates interference, then it is denoted “+”, partial inhibition. If the indicator strip growth 
is well demarcated at the junction of the producer strip, then it is denoted with “++”. Indicators 
that are interrupted beyond the edge of the producer strip are denoted by “+++” if narrow 
clearing and “++++” if wide clearing.  
x. Non-discernible results 
In cases of equivocal growth after 18 hours of incubation at 37 degrees Celsius and 5% carbon 
dioxide, the culture medium was re-incubated for further 24 hours. The procedure is repeated 
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for a further 24 hours if no growth is observed; persistent non-growth medium was then 
discarded after day 3.   
e. Results: 
OMIVI study had 441 obtained ear swabs, 269 samples were lost over the 9 years of storage, 
multiple transits to various storage sites, un-identifiable due to loss of the identification stickers, 
leaving this trial with 172 traceable specimen numbers with identifiable otopathogen strains. 
(see Figure 4-1) These were sub-cultured out of the frozen STGG isolate suspension. Sixty-
five samples had no growth of the previously labelled isolated species, leaving a total of 107 
successfully sub-cultured isolates. (see Table 4-1). 
BLIS produced by S. salivarius K12 against standard control indicators suggests the production 
of both Salivaricin A and B in both types of culture medium. However, the growth of 
Streptococcus constellatus appears to be more florid in the HTM agar when compared to that 
of the hBaCa agar. (see Figure 4-2)  
Overall, 51 of the 107 (48%) isolates have growth inhibition from BLIS produced by S. 
salivarius K12. Twenty of the isolates demonstrated “++++” response, 16 demonstrated “+++”, 
5 with “++” and 10 demonstrated “+”. Fifty-two per cent of the isolates had no appreciable 
growth restriction from bacteriocin produced by S. salivarius K12. (see Table 4-2) 
All of the 9 S. pneumoniae isolates were inhibited by BLIS produced by S. salivarius K12. 
Equally, all T. otitidis, Corynebacterium sp. and A. otitidis also demonstrated a full response to 
the BLIS inhibition.  
M. catarrhalis isolates demonstrated a partial response to the BLIS produced by K12. Sixteen 
of the thirty-one demonstrated no inhibition to growth from BLIS, while 10/32 demonstrated 
“+” and 5/32 demonstrated “++”.  
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None of the 34 H. influenzae had growth inhibition from the BLIS produced by the S. salivarius 
K12 on the HMT. 
  





172 identifiable Isolates received for this trial:
S. pneumoniae 11 H. influenzae 56
M. catarrhalis 36 Corynebacterium sp.. 7
S. pyogenes 1 S. aureus 6
S. ludgenesis 1 A. otitidis 35
T. otitidis 15 P. aeruginosa 3
Yeast 1
107 Samples contain identifiable organism:
S. pneumoniae 9 H. influenzae 34
M. catarrhalis 31 Corynebacterium sp.. 1
S. pyogenes 1 S. aureus 4
S. ludgenesis 0 A. otitidis 13
T. otitidis 10 P. aeruginosa 3
Yeast 1
65 Specimens had no culturable organism
Figure 3-1 OMIVI trial otopathogens isolates 













Strain specification  Activity  
1  M. luteus strain T-18  +++  
2  S. pyogenes (Group A)2 strain FF22, M – type 52, T-
pattern 3/13  
+++  
3  S. anginosus (Group-F) strain T-29  +++  
4  S. uberis (Group-E) strain T-6, (ATCC 27958)  +++  
5  S. pyogenes (Group A) strain 71-679, M-type 4, T-
pattern 4  
+++  
6  L. lactis (subsp. lactis)  +++  
7  S. pyogenes (Group A) strain 71-698, M-type 28, T-
pattern 28  
+++  
8  S. pyogenes (Group A) strain W-1, M-type 87, T-
pattern 6  
+++  
9  S. equisimilis (Group-C) strain T-148  +++  
A. HTM B. hBaC
Figure 3-2: S. salivarius K12 Controls on HTM d hBaCa agar. 
S. salivarius K12 BLIS activity against the standard indicators in the HTM and hBaCa 
culture medium. Vertically orientated streak is the producer streak containing BLIS 
produced by S. salivarius K12. The h rizontally orientated streak is the standard set 
of indicator species 1-9 in descending order M. luteus (strain T18), S. pyogenes (strain 
FF22). S. constellatus, S. uberis, S. pyogenes (strain7179), L. lactis, S. pyogenes (strain 
71698), S. pyogenes (strain W1) and S. equisimilis. Overall demonstrating strong 
inhibition in the presence of BLIS Production. 
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Table 4-1: OMIVI trial otopathogens overall survival  
 
f. Discussion: 
This study is the first to test a commercially available probiotic against otopathogen strains 
obtained from children with documented ear disease. This is an essential step before the 
possible use of probiotics to prevent AOM. Santagati and colleagues have shown that BLIS 
inhibits the growth of potential pathogens isolated from the oral cavities of healthy children 
(135). This study adds to this by testing the inhibitory potential of BLIS against bacteria 
isolated from middle ear fluid of children with a history of recurrent AOM or OME.  
As mentioned in chapter 2, the literature review, immunisation against S. pneumonia has not 
been an effective strategy for reducing the incidence of AOM (4,60). Carriage rates in children 
Organism Survived trackable isolates Percentage 
A. otitidis 13 35 37.1% 
T. otitidis 10 15 66.7% 
P. aeruginosa 3 3 100.0% 
Yeast 1 1 100.0% 
S. aureus 4 6 66.7% 
S. pneumoniae 9 11 81.8% 
M. catarrhalis 31 36 86.1% 
Corynebacterium spp. 1 7 14.3% 
H. influenzae 34 56 60.7% 
S. pyogenes 1 1 100.0% 
S. lugdunensis 0 1 0.0% 
Total Isolate Survival 107 172 62.2% 
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of S. pneumoniae strains resistant to antibiotics remain high in some populations despite 
immunisation (136). Therefore, probiotics could be an effective alternative to the repeated use 
of antibiotics in otitis media prone children.  
All strains of the S. pneumoniae, Corynebacterium sp., A. otitidis and T. otitidis were inhibited 
in growth in BLIS enriched culture mediums. S. pneumoniae has a high carriage rate in otitis 
media prone children and is the most common bacteria causing AOM (137). The other Gram-
positive bacteria isolated in this study include Corynebacterium sp., A. otitidis and T. otitidis. 
However, these organisms’ role in otopathogenicity remains controversial, as they are common 
commensal organisms isolated in the ear canal (138,139). Nonetheless, the pathogenic potential 
has been well supported by authors that had isolated these organisms via sterile 
tympanocentesis (138,139). The data from this study suggest that S. salivarius K12 has the 
potential to be used as a probiotic for the prevention of AOM due to gram-positive organisms. 
Bacteriocins usually kill bacteria that are closely related to the producing strain, whilst the 
producing strain usually shows immunity (140). Therefore, it is not entirely unexpected that 
BLIS produced by S. salivarius K12 does not inhibit the growth of some of the Gram-negative 
bacteria, in particular, H. influenzae. However, S. salivarius K12 BLIS was able to exhibit 
some inhibition of growth to M. catarrhalis and Pseudomonas aeruginosa, which has not been 
previously demonstrated. 
g. Conclusion 
This study demonstrates for the first time that a commercially available probiotic strain S. 
salivarius BLIS K12 can inhibit the in-vitro growth of the most common pathogens causing 
AOM. Given the high incidence and prevalence of AOM in children, the use of probiotics could 
potentially have an impact on one of the most common infections in children. 
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h. Strengths and weaknesses of the current study and future study directions 
One of the strengths of the study is that all the bacteria tested were isolates from the middle ear 
fluid of children with documented ear disease. It is, therefore, likely that these isolated 
pathogens were all involved in the pathogenesis of the children’s ear infections and therefore 
any inhibition demonstrated by the BLIS K12 probiotic has the potential to be clinically 
relevant. Despite the isolates being subjugated to a long period of storage, previous defrost and 
refreeze procedures, this experiment has achieved culturable live bacteria in 62.2% of the 
isolates. Out of these isolates, a good representative of the otitis media pathogens was 
culturable and had good inclusion of the three most common otopathogens. This experiment 
has demonstrated that the S. salivarius K12 is a potent inhibitor of the S. pneumoniae and has 
demonstrable activity on M. catarrhalis, T. otitidis and A. otitidis. Overall, nearly half of the 
pathogenic species had demonstrable inhibition from BLIS, and in turn, hints at the plausibility 
of clinical role in some otitis media cases. Nonetheless, the non-universal pattern of inhibition 
of the otopathogens may account for the heterogeneity of the literature. 
The main limitation of this study is the in-vitro nature of the testing. The environment in which 
the BLIS production and bacterial interference have been evaluated does not replicate the in-
vivo environment of the active disease process. Furthermore, since the H. influenzae failed to 
grow on hBaCa agar, a different test medium (HMT agar) was used, and it is not known how 
much BLIS production was obtained on this growth medium.  In-vitro BLIS production is 
known to be strongly dependent on the culture medium composition (140). This experiment 
did, however, demonstrate that the S. salivarius p-typing was similar in both media, hinting at 
an equitable production of BLIS. 
Nonetheless, the efficacy of BLIS in these environments can be variable, and the interaction 
with the pathogen is therefore unknown. Regrettably, the majority of the samples from the 
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initial OMIVI study has not survived the transcriptions, transits, storage, or did not have 
culturable live bacteria. One species that were documented but had no culturable sample was 
S. lugdunensis. Overall, fifty-two per cent of the isolates were not inhibited directly by the 
BLIS of S. salivarius K12, but this experiment was unable to evaluate the other mechanism of 
action by probiotics. Therefore, this experiment is unable to postulate the in-vivo effects of S. 
salivarius K12 may have on the pathogenesis of otitis media. 
Further studies will need to emphasise the in vivo inhibition and also the clinical safety and 
efficacy of probiotics and dosing. The in vivo nature of future studies may also shed insight 
into the alternative mechanisms in which probiotics work to prevent disease, other than direct 
inhibition. To advance the idea further, this thesis has proposed to investigate further whether 
it is possible to colonise the nasopharynx with S. salivarius K12 and in turn set up for future 
directions.  
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Table 4-2: Range of inhibition scores from S. salivarius K12 deferred antagonism testing against otitis media pathogen isolates. N= the number of 
isolates; " – "= no inhibition; " + " to " ++++ " indicate inhibition, but the varying diameter of zone of inhibition; last column denotes the overall 
rate of inhibited growth of the otopathogen.  
Organism - % + % ++ % +++ % ++++ % Total 
A. otitidis (n=13) 0 0% 0 0% 0 0% 0 0% 13 100% 100% 
T. otitidis (n=10) 0 0% 0 0% 0 0% 8 80% 2 20% 100% 
S. aureus (n=4) 3 75% 0 0% 0 0% 1 25% 0 0% 25% 
S. pneumoniae (n=9) 0 0% 0 0% 0 0% 5 56% 4 44% 100% 
M. catarrhalis (n=31) 16 52% 10 32% 5 16% 0 0% 0 0% 48% 
Corynebacterium spp. (n=1) 0 0% 0 0% 0 0% 0 0% 1 100% 100% 
Non-typeable H. influenzae 
(n=34) 
34 100% 0 0% 0 0% 0 0% 0 0% 0% 
S. pyogenes (n=1) 0 0% 0 0% 0 0% 1 100% 0 0% 100% 
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CHAPTER 5 - COLONISATION STUDY  
Inhibitory effects of probiotics use on nasopharyngeal pathogen COloNisation Trial (ICON 
trial) – Trial is registered with Australian New Zealand Clinical Trial Registry: registration 
number ACTRN12619000779178 
a. Introduction 
In the previous chapters, this thesis has established the lack of consensus in the available 
literature on the benefit of probiotics in the prevention of acute otitis media in children. The 
heterogeneity in the literature is likely multifactorial. Chapter 3 demonstrated that whilst 
probiotics S. salivarius K12 BLIS can be an effective inhibitor to growth for S. pneumoniae 
(100% inhibition rate), it cannot effectively inhibit the growth of M. catarrhalis (48%) and 
NTHi (0%). However, the main limitation of the direct inhibition study was the in-vitro nature 
of the study, making the extrapolation to the nasopharynx and the real-world interaction 
difficult.  
In chapter two, 9 author groups have inoculated the otitis-media prone children with oral dosing 
of probiotics whilst the remaining 4 groups of authors used trans-nasal administration (89,94–
105). Only one of these groups has primarily investigated whether the prescribed probiotic had 
colonised the targeted population, with 6 out of 18 showing colonisation (103).  
Although there are multiple mechanisms with which the probiotic may confer its beneficial 
effect, the most prevalent and widely published theory remains direct inhibition to growth and 
competition for finite resources  (71). Furthermore, nasopharyngeal carriage of otopathogens 
is well established with AOM in children (19). Therefore, for probiotics to reduce the risk of 
AOM, the probiotic species must colonise the nasopharynx to rid of otopathogens from the 
nasopharyngeal microflora. Oral probiotics have been used by various author groups, as 
Tzu Yu Chen MMedSc 2022556 
66 
 
presented in chapter 2. Although, it is possible that nasopharyngeal regurgitation could lead to 
oral probiotics reaching the nasopharynx, anatomically and physiologically this is more 
challenging, due to the function of the soft palate. (141) Hence, trans-nasal administration of 
the probiotics is likely more effective in colonising the nasopharynx (142). 
Previous work by a masters student (Anneleen Hendrickx) has demonstrated good tolerability 
of nasal drop probiotics in children (86). This current study set out to replicate their study result 
and to further investigate the colonisation rate and also the microflora composition change.  
b. Aim/Research Question 
This study aimed to evaluate the ability to colonise the nasopharynx with S. salivarius BLIS 
K12 delivered via trans-nasal drop compared to an oral lozenge. Secondarily, this study aimed 
to establish if successful colonisation led to a reduction in otopathogen species in the 
nasopharynx. 
Thirdly, tolerability of the administration process was recorded and any adverse event from the 
probiotics was monitored. 
c. Hypothesis 
The hypothesis was that colonisation of S. salivarius is achievable and that quantitively at 
higher concentrations when administered through the trans-nasal route compared to an oral 
lozenge. Secondarily, the successful colonisation of probiotic S. salivarius leads to a change in 
the nasopharyngeal composition with a reduction of otopathogen colonisation in the 
nasopharynx. 
Thirdly, tolerability would be equitable between the two arms of administration. 




i. Trial design 
To test the hypothesis, a randomised trial was conducted. The participants were randomly 
allocated into trans-nasal or trans-oral administration of the probiotic S. salivarius K12. Pre-
probiotic nasopharyngeal microfloral compositions were objectively compared to post-
probiotic compositions via the real-time quantitative polymerase chain reaction (RT-qPCR) 
technique. Blinding of the participants was not possible due to the different routes of 
administration. Blinding of the assessor was also not possible as the primary researcher is also 
the primary recruiter and the interviewer. Placebo control was not included in the trial design. 
ii. Participants and recruitment 
Fifty healthy adult volunteers were enlisted, via advertisement at the local ENT clinic and the 
local university. All potential participants were given an information sheet that explained the 
study in plain English. Informed consent was obtained from all participants. Participants were 
screened at commencement for potential confounding factors. Individuals were excluded from 
the trial if there is one or more of the following: other concurrent probiotics or antibiotics use, 
active or recent rhinosinusitis, concurrent nasal steroid or oral steroid use, significant 
background medical illness. Participants were not blinded but were randomized into the nasal 
drop or the oral lozenge arm (25 participants in each arm). Both arms of the study contained 
active S. salivarius. (see below) The information sheet and the consent form are attached in 
appendix 4 and 5, respectively. 
Despite AOM being a primary childhood disease, this study utilised adult volunteers for a few 
major reasons. The primary consideration was that this is a colonisation study with the main 
aim to study colonisation and not the effect on AOM. Therefore, perceivable benefits of 
altering nasopharyngeal microfloral composition are theoretical. Although the S. salivarius’ 
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safety has been previously published, the trans-nasal dosing’s safety remains uncertain. The 
tolerability of nasopharyngeal swabs in children is likely more problematic due to a smaller 
nasal cavity. Therefore, consenting children for the study was considered unwarranted and 
unnecessary. 
iii. Nasopharynx sampling 
Nasopharyngeal swab for the sampling and determination of nasopharyngeal microflora 
composition is a well-established technique (106). This was carried out by the primary 
investigator (Tzu Yu Chen). The participants were given the option to have their nasal cavity 
sprayed with co-phenylcaine nasal spray (Lignocaine hydrochloride 50mg/l and phenylephrine 
hydrochloride 5mg/ml. ENT Technologies, Hawthorn, Australia). Those that received the 
spray waited for 5 minutes to allow for decongestion and adequate topical anaesthesia. The 
nasopharynx was sampled with flocked swabs manufactured by BD™ (USA). To facilitate the 
correct sampling of the nasopharynx and minimize contamination from the microflora of the 
nasal vestibule, Thudicum nasal speculae were used to prevent the swab end contamination at 
entry and exit. Care was taken to ensure that upon entry and on the withdrawal of the swab, the 
microbiota sampled remained that of the nasopharynx and that the swab was only in contact 
with the nasal respiratory epithelium during the sampling procedure. 
The tip of the flocked swab was inserted into the transport medium STGG broth (see below) 
immediately.  
Nasopharyngeal sampling was taken at enrolment pre-randomization into the different arms of 
the study. The participants were then given a week course of antibiotics and randomised into 
one of the two arms of receiving probiotics. (see below) Following the completion of the two-
week course of probiotics, the participants had a one-week washout period before the 
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subsequent follow-up swab. Therefore, each individual had one pre-probiotic swab and one 
post-probiotic swab. 
iv. Transport and storage of the nasopharyngeal samples 
The transport medium was standard skim milk, tryptone, glucose and glycerol (STGG) broth 
with the following composition: Skim milk powder 2 g, Tryptone soya broth 3g, Glucose 0.5 g, 
Glycerol 10 ml, and suspended with Distilled water 100 ml, commercially prepared by 
Canterbury Health Laboratories (LTD). The STGG broth was dispensed in 1ml aliquots in 
micro-centrifuge tubes. Flocked swabs containing the samples were used in the manner 
described above and inserted into the broth. The handle of the swab was shortened, and the lid 
of the container was tightened securely. The broth with embedded swab tip was transported to 
the local medical laboratory within 4 hours to be vortex at high speed before storing in the 
freezer controlled at -20°C. 
The stored specimen was then gathered weekly and transported to Dunedin for more extended 
storage whilst waiting for the completion of the entire recruitment and follow up process. The 
transport process encompassed the frozen specimens shift from the freezer to the -20°C 
condition by placing the samples in polystyrene insulation boxes filled with dry ice. Upon 
reaching Dunedin, the specimens were placed into freezers again stored at -20°C. 
v. Pre-colonisation antibiotics 
Participants were given a week course of antibiotics before receiving the probiotics course to 
effect a temporary reduction in the levels of their native oral streptococcal populations to 
facilitate subsequent colonisation by the S. salivarius K12 in the probiotic formulation. Non-
penicillin allergic participants received a course of co-amoxicillin-clavulanic acid of 
500mg/125mg orally, twice daily for 5 days, whilst those with reported penicillin allergy were 
given a course of erythromycin 400mg twice a day equally given for a 5-day course. 
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vi. Power calculation and Randomisation procedure 
The sample size was calculated on the statistical significance of 5% and a power of 80%. Based 
on the anatomical arrangement and the physiology of swallowing we anticipated a lower 
colonisation rate when the probiotics are introduced orally. When compared with introducing 
the probiotics through the nasal passage, we anticipated a much higher rate of colonisation. 
The pilot study done by previous Master’s student Dr Anneleen Hendrickx had yielded results 
suggestive of 100% colonisation (unpublished result, based on personal communication). The 
recruitment size of 50 should have therefore provided enough power to determine at least 30% 
difference in colonisation, whilst allowing for 10% being lost to follow-up.  
The allocation of the study participants into trans-nasal or trans-oral administration of the 
probiotics was randomised. Randomisation was done with a 1:1 ratio into each arm and 
achieved via Sealed Envelope Ltd. 2021. Simple randomisation service. [Online] Available 
from: https://www.sealedenvelope.com/simple-randomiser/v1.  
vii. Probiotics colonisation  
After the week course of antibiotics, the participants were randomized into the two arms of the 
trial. The oral lozenge group were given the standard Daily Defence BLIS K12™ (Vanilla 
flavour; contains at least 1.25 billion colony forming units (CFU) at the date of manufacture), 
with instruction to take one lozenge twice a day and do so after dental routine and to avoid 
eating and drinking for at least 30 minutes after ingestion. The nasal formulation group were 
given freeze-dried S. salivarius K12 in powder format and instruction on resuspension into a 
mixture of sesame oil with tween 80 (polyoxyethylene sorbitan monooleate, non-ionic 
surfactant) prior to use. This group also had been given a printed instruction sheet on the use 
of the nasal drop of two drops per nostril twice per day (2.5 billion CFU/day). Participants were 
instructed to blow their nose and to lay flat before instilling to facilitate the nasal drop 
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containing the probiotic reaching the nasopharynx. To prevent contamination of the probiotic 
suspension from the nasal dropper after instilling and touching the nose, the participants were 
also requested to sterilize the dropper by placing it into boiling water for 5 minutes after each 
use.  
viii. Statistical analysis 
Participants’ age, gender, and smoking status were collected. With the exclusion criteria being 
stringent the healthy volunteers had no other medical co-morbidities. The basic demographic 
would be presented in tabular form. The proportion of participants who were colonised would 
be calculated by counting the number of participants with demonstratable S. salivarius in the 
post-probiotic swab divided by the total number of participants in the arm (n=25), using 
intention-to-treat analysis. Fisher exact test would be used to compare the proportion of 
participants colonised between the trans-nasal and the trans-oral group. Alteration in the 
composition of the otopathogen (S. pneumoniae, M. catarrhalis, H. influenzae) within the 
microflora will be compared using ANOVA analysis.  
ix. Microbiological analysis 
Real-time quantitative polymerase chain reaction (RT-qPCR) allows qualitative and 
quantitative analysis of the probiotic species before and after colonisation. This technique also 
allowed us to determine the relative quantities of the otopathogens of the nasopharynx. Please 
see below for a detailed description of the qPCR technique. All experiments were conducted 
in duplicate to ensure reproducibility. S. salivarius K12 colony suspended in sterile water 
served as a positive control to ensure the PCR reaction plate, and the master mixtures (see 
below) were prepared correctly. Similarly, sterile deionized water was used as a negative 
control to ensure that the mixtures were not pre-contaminated. 
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x. Tolerability assessment 
This studied primarily focused on the ability to colonise the nasopharynx with probiotics. 
Adverse events were monitored throughout the intervention period and during follow up. 
Reported adverse events were recorded. At the conclusion of the study, participants were asked 
about the intervention and whether allocated probiotic formulation was tolerated. If participants 
had failed to complete the course of probiotic as instructed, reasons for the discontinuation 
were also asked. Together the adverse events recording and participants reasons for 
discontinuation formed the basis for tolerability. 
e. Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) 
i. Process of RT-qPCR 
Polymerized chain reaction (PCR) is a deoxyribose nucleic acids (DNA) analysis method 
commonly used to rapidly multiplicate copies of a specific DNA sequence. This rapid 
multiplication process allows scientists to take a small sample of initial template DNA and 
amplify it to a large enough amount to study in detail (143).  
Polymerase chain reaction initiates by denaturing the template DNA and its binding and 
packing proteins. The process involves heating the sample (to 95°C) to break the hydrogen 
bonds. This heating process ensures that the template DNA's are single strands. The mixture is 
then cooled to 60°C. The second step in the process involves the binding of the specific primers 
(forward and reverse) to the template (annealing). Once bound, the DNA polymerase, an 
enzyme the attach nucleotides onto the primer sequence matching that of the template strand, 
extend the chain. The process is then repeated and thus through each cycle, the number of 
copies of the DNA doubles (144).  
Real-time qPCR is a novel technique that couples amplification of a target DNA sequence with 
quantification of the concentration of that DNA sequence in the reaction well (145). It is a 
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technique that allows quantitative analysis of the template DNA if a known concentration 
sample was analysed simultaneously to provide the standard curve. Differing from the standard 
PCR technique, the master mixers of the qPCR contain specific fluorescent probes that will 
attach to the target DNA and provide the machine with a real-time photo-fluorescent signal 
proportional to the concentration of the target DNA. As the polymerase chain reaction proceeds, 
the template will double with each subsequent cycle. Therefore, compared to a standard sample, 
the amount of starting templates is quantified. 
Using PCR in the identification of bacterial species and strains is not new, amplifying the 
variable portions of the 16S rRNA gene provide unique signatures that can provide an 
identification of the bacteria species in the sample (146). However, utilizing a combination of 
variable region and specific sequence 16S rRNA allows for simultaneous species identification 
(147). 
ii. Primers and Probes for RT-qPCR 
Primers are sequences of the nucleotide that initiate the transcription process (143). Reid and 
colleagues have previously used Primer3Plus software (v2.2.6) to design PCR primers and 
probes for the identification of S. salivarius and more specifically, K12 (148).  
For this study primer sequences were 16S salivarius V1-V2  
 Forward: 5'd GAGGAGCTTGCTCTTCTTGGA 3' 
 Reverse: 5’d GTTATCCCCCGCTACAAGGC 3’ 
Both sequences are manufactured by Biosearchtech™ (Petaluma, CA, USA).  
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iii. Master mix 
The master mix can be commercially prepared mixtures of reagents that facilitate the PCR 
process. The content contains nucleotide bases, heat-stable DNA polymerase, a co-factor 
(magnesium chloride or sulphate), and buffers.   
For this study, SYBR™ Green PCR Master Mix (ThermoFisher Scientific, New Zealand) was 
used. The DNA template was provided into the reaction by taking a small (4 μL) aliquot from 
the STGG broth was mixed with the master mix and ran through the QuantStudio 6™ Flex 
Real-Time system (Applied Biosystems). 
iv. S. salivarius  identification using RT-qPCR 
a) Introduction 
Multiple known species within the upper aerodigestive tract are known for bacteriocin 
production (82). RT-qPCR assay previously developed for strain K12 had targeted salA, a 
megaplasmid-borne gene encoding the bacteriocin salivaricin A2 (148). Unfortunately, due to 
the presence of S. pyogenes and its known ability to produce the same bacteriocin, when used 
alone, the test specificity is low (149). Similarly, the species S. mitis with non-K12 strains of 
S. salivarius are common in the human oral cavity. Therefore, sboA, another megaplasmid 
encoded lantibiotic salivaricin B, is unsuitable to be used alone for specificity (149).  
b) K12 identification 
Extensive work has been done previously to identify K12 strain amongst the S. salivarius 
species utilizing the TaqMan™-based RT-qPCR technique (148). Due to the biodiversity as 
mentioned above of the upper aerodigestive tract and the diverse range of organisms that 
demonstrate the ability to produce the same bacteriocins specificity for K12 requires the 
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identification of the different region sbo. Thus, to positively identify the organism S. salivarius 
K12, it needs to have present, sboA, sboG and sboK. 
v. Overall Process of RT-qPCR 
RT-qPCR analysis of the samples was carried out by combining the forward and reverse 
primers (0.3 μL of each) with the master mix containing the PerfecTa SYBR® Green fast mix 
(5 μL) and microbiome DNA sample from the nasopharyngeal swabs (4 μL). Sterile PCR-grade 
water was then added (0.4 μL) to make 10microl-litre (μL). The PCR mixture is placed in a 96-
well reaction chamber, and the TaqMan qPCR assays were run on a QuantStudio 6 Flex Real-
Time System (Applied Biosystems) using the following thermal cycling parameters: initial 
denaturation at 95 °C for 10 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min.  
f. Results 
i. Overview 
This study recruited a total of 50 individuals and randomized them into the two arms with 25 
in each arm (nasal versus oral probiotic formulation). One volunteer of each of the trans-nasal 
and the trans-oral group were lost to follow up and therefore did not have a follow-up swab. 
Furthermore, 6 out of the 23 remaining trans-nasal probiotic participants did not complete the 
full course of the nasal drops due to various reasons, see Figure 5-1. The anonymized data 
collection sheet is attached in Appendix 3. This leads to a total of 18 that completed the nasal 
probiotics and 24 that completed the oral lozenge.  
This study had recruited 44 female and only 6 male volunteers. The ratio of male to female in 
both arms was identical (3 male in the oral group and 3 in the nasal). The average age of the 
entire cohort was 41.6 years of age. Out of the 48 that we have followed up with a post-probiotic 
swab, it was taken on average five days later than the initial proposed (longest = 93 days after 
the cessation of the probiotics). Forty-two out of forty-eight (87.5%) completed the prescribed 
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antibiotics and probiotics course. Due to the poor-rate (3/24) of nasal bottle return, no result 
was available on the average use.  
A select sample of the nasopharyngeal swabs (containing both pre- and post- probiotics swabs) 
was tested for any bacterial DNA presence, this was done simultaneously with known samples 
of S. salivarius K12, S. mitis, S. pyogenes (positive controls), and sterile water (negative 
control). This test run of the samples failed to demonstrate any bacterial content in the 
nasopharyngeal swabs. The number of cycles that were needed for the fluorescence to reach a 
quantification threshold for the swab samples were similar to that of the sterile PCR-grade 
water. In turn, inferring low template counts and hence are not able to be interpreted.  
In an attempt to concentrate the sample and potentially increasing the titre of bacterial content, 
the original swab broth was centrifuged at 13,000 rpm for 5 minutes to form pellets. The pellet 
was then taken and re-suspended in 200μL, leading to a 5-fold concentration. Despite this 
concentration manoeuvre, the number of cycles that were needed for the fluorescence to reach 
threshold remained above 30, indicating a very low bacterial DNA level and therefore 
indistinguishable from the sterile water used to prepare the RT-qPCR.  
This initial trial testing meant that a significant portion of the experiment could not be carried 
out from the original research proposal. With little to no overall DNA template level within the 
sampled specimen, attempting to sub-classify S. salivarius K12 was not feasible. Similarly 
testing the sterile nasopharyngeal samples for otopathogen species were not carried out. 
The lack of any bacterial DNA templates in the nasopharyngeal swabs, which one would expect 
at least the normal healthy microflora, meant that this portion of the experiment was unable to 
draw any conclusions on the ability of the S. salivarius to colonise the nasopharynx. Similarly, 
the sterile nasopharyngeal samples made it impossible to demonstrate the microbiome 
composition change of the nasopharynx from probiotics use. 








Total of 50 participant 
recruited through local ENT 
clinic and university. 
25 randomised to nasal 
probiotics  
25 randomised to oral 
probiotics 
18 completed nasal 
probiotics  
24 completed oral 
probiotics  
- 1 lost to follow up 
-  2 did not complete 
due to taste 
- 2 did not complete 
due to nasal 
crusting 
- 2 did not complete 
due to tediousness 
Figure 5-1: Flow chart of the participant recruitment, randomisation and drop out. 
- 1 lost to follow 
up 
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ii. Tolerability of the probiotics 
Despite the lack of data for the colonisation, valuable input was obtained from the volunteers 
on the tolerability of nasal drops versus oral lozenge. Overall tolerability was fair, with 31 out 
of the 48 (64.6%) individuals completed their randomly allocated probiotic without adverse 
events. However, 6 out of the 24 in the nasal group did not complete the prescribed course due 
to reasons demonstrated in Figure 5-1 and Appendix 3. Furthermore, of the 18 that did complete 
the full course of nasal probiotics, only 9 had no adverse report. In contrast, the volunteers that 
oral probiotics had a much higher tolerability rate (79.1% had no adverse event). The most 
common adverse report in orally administered probiotics is bloating (n=3). (See Table 5-1) 
Table 5-1: Adverse event reported by intervention group (participants may report one or more 
adverse events) 
Trans-nasal administration Trans-oral administration 
Adverse event (n) Adverse event (n) 
Nasal Crusting 3 Bloating 3 
Foul Taste 6 Foul taste 1 
Dry mouth 1 Dry mouth 2 
Total number 




completed the full 
course 
24 
Total number of 
individuals with an 
adverse report 
10 
Total number of 








The nasopharyngeal swabs failed to contain any appreciable DNA template for the polymerase 
chain reaction. The result was an unexpected and intriguing finding, especially when one would 
normally expect to find at least microflora of the nasopharynx. Previous work by a masters 
student utilized a similar methodology and yielded colonisation data (86) (see  Chapter 2 
section “f”). Similar types of studies by other author groups also utilizing the same technique 
have yielded good microfloral composition data (31,108).  Other authors have utilized RT-
qPCR to look at the gene expression of a single bacterium (150). Therefore, it is intriguing for 
us to have no DNA templates in our swab samples, whilst the positive and negative controls 
yielded results that demonstrated normal running of the biochemical reaction. It was anticipated 
that even if we have no colonisation from S. salivarius, we would be able to demonstrate other 
bacterial species in both before and after nasal swabs.  
Within the recruitment process, the volunteers are predominantly female (n=44) and males 
accounted for only 12% (n=6). Although this is not a representative sample of the population, 
it has been recognised that females are more likely in accepting volunteering requests (151).  
One potential theory behind this intriguing result may be the contamination of the reagents by 
a DNAase and RNAase enzyme and rendering the test samples “empty” of polymerisable 
templates. This theory of contaminated reagents, however, fails to explain the positive reaction 
seen in the positive controls of S. salivarius K12 and S. mitis, as the reagents were used 
universally in all the reaction wells.  
Another theory behind the lack of bacterial DNA template observed during testing could be the 
availability of free DNA versus those interlocked in biofilms (a multicellular community held 
together by a self-produced extracellular matrix) (152). However, this does not explain how 
previous author groups have managed to have bacterial DNA in their nasopharyngeal samples. 
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The biofilm also is known to incorporate bacterial DNA as part of its structural integrity (152). 
Thus, biofilm activity should lead to an abundance of bacterial DNA instead of the observed 
result.  
One other theory was the lack of an additional denaturation step, aside from the QuantStudio 
6 Flex Real-Time System (Applied Biosystems) initial denaturation at 95 °C for 10 min. The 
technique utilised by this thesis, however, is comparable to other authors (148). Therefore, 
although this could be plausible, it is unlikely that further denaturation steps would yield 
different results.   
Another theory to account for the lack of result could be the batch of micro-tubes, and the 
STGG broth may have been contaminated with agents capable of breaking down DNA. Thus, 
during the process of transport and storage, the initial microbiome had been broken down into 
constituents and therefore failed to react with the primer. This hypothesis is possible but unable 
to be tested due to the discontinuation of the source of these consumables, and a new batch of 
the micro-tubes with STGG broth would not be representative of the initial batch. 
It was postulated whether the storage and transportation medium (STGG broth) used in this 
study might have been interfering with RT-qPCR. However,  previous work utilizing the 
standard STGG broth has failed to show any detriments to their results (153,154). Likewise, 
the storage of STGG specimens in this current study is comparable to O'Brien et al., and their 
team had demonstrated significant preservation of microorganisms in STGG medium (155). 
Furthermore, with RT-qPCR analysis, we do not require actual live bacteria and only require 
that of its DNA templates. Therefore, this theory also fails to explain the intriguing results and 
is unlikely to account for the phenomenon.  
Nasopharyngeal microflora can be sensitive to the influence of antibiotics (121). Likewise, S. 
salivarius K12 is also very sensitive to oral antibiotics (122). Though, the use of oral antibiotics 
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pre-colonisation could explain the lack of bacterial DNA on the follow-up swab; the absence 
of bacterial DNA template before the antibiotic and probiotic treatment remains unexplainable. 
Furthermore, it could be that there is a low baseline carriage of the microbiome in healthy 
individuals. Such that, volunteers should be sourced from individuals with acute otitis media. 
This is, however, unlikely as Rawlings et al. have previously demonstrated the carriage of 
otopathogens in both health and illness states (156).  
Despite the lack of colonisation data and the inability to assess the primary aim and hypothesis, 
this study did obtain some invaluable information. Overall good follow up rate was achieved, 
and the tolerability of probiotics administered in both routes was reassessed. Contrary to the 
excellent tolerability reported in the work of Dr Hendrickx (86), this was not replicated in this 
study. The overall tolerability is fair, tediousness and the poor after-taste were the main adverse 
events with the nasally administered S. salivarius K12, whilst bloating were the most common 
in the orally administered counterparts. Furthermore, there were 3 significant adverse events 
with nasal crusting and purulent discharge, which could indicate inflammation or infection of 
the nasal passage. One individual has a background of rhinosinusitis and commenced on topical 
nasal steroids after the initial recruitment. The other individual had complete resolution of the 
nasal crusting and discharge with the cessation of the probiotic nasal drops without further 
intervention. 
Interestingly, one volunteer had resolution of their nasal crusting from the use of nasal S. 
salivarius K12. The main difference between this study and that of Dr Hendrickx was the age 
group of the recruited. The discrepancy in the reported adverse event may be multi-factorial. 
However, young children could be less likely to report adverse medication reactions (157).  
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h. Strengths and limitations of the current study and future directions 
In this study, high follow-up rates were achieved, as the primary investigator is actively 
involved in the follow-up process. The compliance with oral probiotics was high (100%). 
However, compliance with the nasal probiotic only reached 75% (18/24). The reason for non-
compliance was asked and documented at the follow-up interview (see Figure 5-1). The 
reduced compliance was relayed back to the Blis technologies, and further research can be 
focused to reduce the tediousness of instillation and to reduce the crusting of the nose and 
improving the taste of the drops to facilitate better compliance.  
Unfortunately, due to the lack of results, no conclusion can be drawn on the efficacy of 
colonisation through nasal or oral probiotics. We also cannot draw any conclusions on the 
efficacy of altering the nasopharyngeal composition, particularly on the ability to suppress the 
growth of the otopathogens. Future investigation will need to investigate whether the same 
specimens could be sub-cultured into an agar medium to amplify the DNA templates before 
resuspending them into sterile water for RT-qPCR analysis.  
Realtime-qPCR relies heavily on the fluorescent probes and the detection of the fluorescence. 
It would be plausible that the yellow hue of the STGG broth reduces the detection. The effect 
of the yellow hue can be determined by further studies that compare the floresence curve 
between known DNA template concentration suspended in STGG versus in sterile PCR water. 
However, as aforementioned other author groups utilised the same methodology and have 
yielded good interpretable results. 
Apart from repeating the experiment, it is difficult to pinpoint the exact mechanism in which 
the test has failed. Repeating the experiment with recruiting a small number of volunteers and 
repeating the swabs could be valuable. Culturing the nasopharyngeal swabs would in hindsight 
provide invaluable evidence on the microfloral sampling adequacy which unfortunately was 
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not pre-conceived. Alternatively, the volunteers could be sourced from individuals with acute 
otitis media and could mean a higher bacterial count. 
The tolerability result demonstrated in this study was incongruent to previous work by other 
authors, which meant that further targeted research should be implemented. The compliance of 
a prescribed treatment is heavily influenced by its tolerability. Therefore, for nasal probiotics 
to be widely implemented for otitis media prone children, the tolerability and the adverse event 
profile needs to be improved.  
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CHAPTER 6 – SUMMARIES, CONCLUSIONS AND FUTURE 
RESEARCH DIRECTIONS. 
a. Summary of the chapters 
Introduced in chapter one, the middle ear is a special place and has fundamental functions on 
the conduction and amplification of sound in hearing. The anatomical construct of the middle 
ear, however, makes it susceptible to micro-organism invasion and infection from the 
nasopharynx through the communicating Eustachian tube. Infection and inflammation thereby 
impair the function of the middle ear and may result in hearing loss.  The infection and 
inflammation not only pose an immediate effect on the individual but also threatens the 
individual's long-term outlook on the ability to engage in social interaction and academic 
performance through hearing impairment. In this chapter, I have also introduced the most 
common micro-organisms that cause middle ear infections and how they evade the host's 
immune system and induces their pathogenicity. Chapter one also presented the endeavours 
and the optimism placed on vaccination to prevent acute otitis media. However, even though 
vaccination has reduced the rate of otitis media induced by the vaccine-associated strains, it 
fails to alter the overall prevalence of childhood otitis media. Probiotics were then introduced 
as a new field of preventative medicine that could be investigated, one which has minimal side 
effects and good tolerability. Chapter one also discusses the mechanism of action of probiotics, 
the fields in which they have shown beneficial impact and the promise they may have in AOM 
prophylaxis. One particular way of pathogen inhibition – bacteriocin like inhibitory substances, 
was emphasised.  
In chapter three, a comprehensive literature review was undertaken to investigate the use of 
probiotics as a preventative measure for acute otitis media. The results were ambiguous and 
conflicting. Though some authors have drawn firm conclusions on the usefulness of the 
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probiotics in preventing otitis media, the results were not unanimous amongst all author groups. 
The overall quality of the study design was flawed with some studies highly susceptible to 
confounding factors. Therefore, it was difficult to draw broad conclusions. The meta-analysis 
of the 5 most homogenous studies (of the total 13 studies) was presented and demonstrated no 
overall prophylactic effect. Despite this, one of the groups did show a modest preventative 
effect against AOM.  
The review of published literature consists mainly of studies conducted with a patient 
population in a clinical setting. Although this format of study design is good at determining 
whether an intervention has any clinical benefit, it does not address the underlying basic science 
behind the intervention. With this in mind; this thesis was set out to determine some of the 
basic science behind probiotics and their use for acute otitis media. In turn, shedding light on 
why the results vary so much between the author groups and what could be improved or further 
investigated before designing another clinical patient-based study.  
S. salivarius strain K12 is a probiotic that is commercially available and has been previously 
trialled by a few author groups for prophylactic use for upper respiratory tract bacterial 
infection. It is a known strain that produces BLIS. Its safety was established and well-tolerated. 
For this reason, this thesis has chosen S. salivarius K12 to answer the basic science and to 
establish its suitability for use in the prevention of acute otitis media in children.  
In chapter four, the proposed probiotic S. salivarius K12, was introduced and was tested to 
determine its inhibitory effect on the otitis media pathogens (obtained through OMIVI trial). 
Although chapter one has covered the various mechanisms in which a probiotic can exert its 
effect, the direct inhibition of pathogen would be one of the primary mechanisms and likely 
the most promising. In this chapter, otopathogens were isolated and cultured. A deferred 
antagonism test was used to determine the efficacy of the BLIS produced by S. salivarius K12 
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in hindering the growth of the otopathogens. Promisingly, inhibitory effect on growth could be 
demonstrated up to 48% of the isolates by S. salivarius K12 BLIS, whilst subgroup analysis of 
the result demonstrated 100% inhibition to S. pneumoniae. The ability to completely inhibit all 
the strains of S. pneumoniae is promising and could provide prophylaxis to strains otherwise 
not included in the vaccination. However, the complete lack of ability to inhibit NTHi and the 
only partial inhibition of M. catarrhalis meant major drawbacks for the probiotic S. salivarius 
to be solely capable of preventing AOMs.  
Concurrently with the study done in chapter 4, the study in Chapter 5 was designed to test the 
possibility of in vivo colonisation of the nasopharynx with S. salivarius. Logically, this would 
need to be established before any clinical patient-based trial investigating probiotics role in 
preventing AOMs. However, despite the sound methodology and process that conforms with 
the previous colonisation attempts by other authors, there were no conclusive results. Potential 
shortfalls were discussed in depth. However, the likely downfall was likely multifactorial and 
further research is required to test the hypothesis of the failure.  
b. Conclusions 
Acute otitis media has a significant burden of disease in children. Unfortunately, despite 
interventions such as ventilation tube insertion, prolonged antibiotics use and vaccination, the 
medical field had minimal success in developing an effective preventative strategy. Conjugate 
vaccination against S. pneumoniae and NTHi has been a theoretically promising endeavour. 
However, the real-world results did not show a clinically significant overall reduction. The rise 
in AOM caused by the non-vaccinated strain has counter-balanced the effect of the decrease in 
AOM by vaccinated strains. Other alternatives including the use of a prolonged course of 
antibiotics in the hope to eradicate the pathogens, is harmful and gave rise to antibiotic 
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resistance, and introduced the dawn of "super-bugs". The lack of prophylactic measures left a 
large population of children who remain susceptible to AOM and its side effects.  
Probiotics are a promising new modality in reducing AOM. Inferring from the probiotics' 
ability to restore balance to the altered microbiome and discourage the growth of pathogens, it 
has lent itself as a promising agent in the prophylaxis to AOM. However, there is a lack of 
overall consensus on the prophylactic properties of probiotics in AOM in the literature. Despite 
some authors claiming good results, the methodology used has resulted in confounding biases. 
The literature review and the meta-analysis carried in this thesis has demonstrated no evidence 
to support the use of probiotics. It is acknowledged, however, that there are large knowledge 
gaps in the literature and this thesis aimed to fill some of these gaps. 
This thesis has tested one of the potential probiotics S. salivarius K12 as an AOM prophylaxis 
measure, by checking its inhibition profile against otopathogens. However, despite good 
demonstrable inhibition to S. pneumoniae, the inhibition was far from universal and therefore 
at best would be a partial measure. Without effective prophylaxis again the other otopathogens, 
it is possible and likely that probiotics will present themselves with the same real-world 
experience as S. pneumoniae vaccination had on AOM. Extrapolation from the in vitro study 
indicated that widespread probiotics use in the population, could lead to the decrease in S. 
pneumoniae related AOM whilst witnessing the rise in NTHi related disease. Nonetheless, the 
100% inhibition rate of S. pneumoniae, meant that S. salivarius may result in better prevention 
of pneumococcal related AOM than t vaccination can provide. This however is highly 
dependent on if the probiotic species being colonisable in the nasopharynx. 
Testing for colonisation of the nasopharynx can be difficult, as demonstrated in this thesis. 
However, the lack of results in chapter 5 is likely due to test failure rather than a genuine lack 
of microbiome in the nasopharynx. The exact mechanism of the failure is not clear and is likely 
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multifactorial. The inherent duplication in the PCR design has failed to serve as a redundancy 
in the test. Nevertheless, the results on tolerability have proved invaluable and indicated that 
further research is needed.  
Overall, there is a lack of available literature to support the use of probiotics for AOM 
prophylaxis. There are multiple reasons which may explain this. One reason may be the lack 
of inhibition to otopathogens and another could be the failure to colonise the nasopharynx. This 
thesis attempted to investigate these two factors and has not been able to demonstrate any 
further evidence to support its use. Therefore, as of currently, there is no indication that 
probiotics have any role in the prophylaxis against AOM. 
c. Future research directions 
The lack of colonisation data from this thesis could mean that in vivo study designs are 
premature at this stage. It would be prudent to instigate research into why the RT-qPCR has 
failed to determine the nasopharyngeal microbiome composition. Firstly, by re-running the RT-
qPCR experiment. Despite this thesis having run the test twice, once with initial concentration 
and further repeat at 5-fold the concentration, it is plausible that further concentration could 
render more interpretable results. However, one would have to question the clinical 
significance of such low concentrations of the microbiome. Alternatively, it would be useful to 
repeat the entire colonisation trial. Recruiting small numbers of volunteers and repeating the 
swabs. Testing the initial, pre-probiotic colonisation swabs to ensure good baseline 
microbiome numbers could provide value, rather than finding the same lack of results at the 
end. Equally, as alluded to in the chapter 5 discussion, volunteers could be sourced from 
individuals with acute otitis media and could mean a higher bacterial count.  
In chapter five, the RT-qPCR quantification mechanism could be impaired by discolouration 
of the STGG broth, and repeating the experiment with suspension in sterile water may be useful. 
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Equally, the transportation and the entire storage of the swabs have been in the STGG broth, 
and contaminants (especially those with DNA breakdown capability) of the broth could 
account for the lack of results. The storage centrifuge micro-tubes could also be contaminated 
with similar agents. These two hypotheses, unfortunately, could not be tested as part of the 
current thesis as the source of those consumable items are discontinued, and any new batch 
will not be the same as those used.  
Research into other probiotic organism alternatives, particular those with higher inhibition for 
otopathogens or even a combination of species, could be fruitful. Especially in preventing a 
rise in non-inhibited species related AOM from over-representation. Universal inhibition of the 
pathogenic species and colonisation with non-pathogenic species would be more likely to lead 
to a protracted downwards trend of AOM.  
Other study targets could be looking into the formulation of probiotics to achieve optimal 
colonisation. The tolerability achieved in this thesis suggests that nasal drops are generally 
poorly tolerated in their current form. The preparation steps required at instillation and the 
process involved in maintaining the sterility of the nasal dropper has reduced compliance. 
Likewise, the twice-daily formulation is tedious and hinders the volunteer to adhere to the 
regimen. The sesame-oil-based suspension is well-liked by some volunteers, whilst others 
found it too pungent for daily use. An increase in compliance would likely entail a higher rate 
of colonisation and likely lead to better prophylaxis. Furthermore, research towards potential 
infection and inflammation secondary to nasal dropper contamination need to be implemented.  
The most optimal route of probiotic administration is still debatable. It has been well 
established that AOM pathogens arise from the nasopharynx. It remains unclear the best route 
of administration to get colonisation of the nasopharynx.  
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The use of antibiotics pre colonisation of probiotics is unfavourable and poses a potential 
barrier for probiotics to be used as a preventative agent. This would need further research to 
investigate its merits. The ideal probiotic preventative organism would not require the host to 
take pre colonisation antibiotics. This aspect of colonisation was not investigated during this 
thesis but would be a valuable characteristic for the ideal probiotic agent to possess.  
Fundamentally, it would be important to demonstrate that one can colonise the nasopharynx 
with a probiotic specie or species that can universally inhibit the growth of otopathogens. This 
would be meaningful before a bedside clinical trial takes place, as lack of culturable 
colonisation and/or lack of universal inhibition likely results in a similar ambiguous and 
conflicting literature. 
Alternatively, another research angle could be investigating an individual's biological response 
to probiotics. Thus, in turn, assessing the alternative mechanisms in which the probiotics may 
confer their benefit. Similarly, the instigation of research into immunomodulation, and how it 
interferes with middle ear health could help provide a fuller picture of probiotics role in middle 
ear health.  
Ultimately, once an ideal probiotic species have been identified, the research will need to tailor 
to the population that are at most risk of AOM. To investigate this sub-set of the paediatric 
population will entail recruiting otitis media-prone children into a double-blinded, randomised, 
placebo-controlled trial. With the given difficulty and ambiguity in assessing AOM, the 
importance of having registered ENT professionals to assess the rate of recurrence of AOM 
would be prudent. Secondary outcome measures may include the rate of need for otitis-media 
prone children for surgical intervention and also essential to assess the tolerability of probiotics.  
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Appendix 2 – In vitro inhibition of otopathogens by probiotic S. salivarius publication. 
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Appendix 3 - Anonymised data collection sheet for colonisation trial 
 
n  M/F 
Study 
arm 









1   F Nasal* 17/10/2019 Augmentin 
14/11/201
9 
18/11/2019 4   
Well-tolerated, episode of URTI 
during probiotics course 
2   F Nasal 17/10/2019 Augmentin 
14/11/201
9 
18/11/2019 4   
Double dipping, nice to moisturise 
in the morning, resolved crusting 
3   F Oral 17/10/2019 Augmentin 
14/11/201
9 
21/11/2019 7   
Well-tolerated taste good, takes 
time to dissolve.  
4   M Oral 17/10/2019 Augmentin 
14/11/201
9 
18/11/2019 4   Well-tolerated taste good,  
5   F Oral 17/10/2019 Augmentin 
14/11/201
9 
18/11/2019 4   Well-tolerated  
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6   F Nasal 17/10/2019 Augmentin 
14/11/201
9 
18/11/2019 4   
Nasal congestion, purulent 
discharge, used concurrent topical 
nasal steroids, build up in the 
pipette 
7   F Nasal 17/10/2019 Augmentin 
14/11/201
9 
18/11/2019 4   Well-tolerated  
8 # F Oral 17/10/2019 Erythromycin 
21/11/201
9 
      Lost to follow up 
9 # F Nasal* 17/10/2019 Augmentin 
14/11/201
9 
   Lost to follow up 
10   F Oral 17/10/2019 Augmentin 
14/11/201
9 
18/11/2019 4   Well-tolerated  
11   F Nasal 21/10/2019 Augmentin 
18/11/201
9 
22/11/2019 4   
Well-tolerated, challenging to 
measure the number of drops 
instilled 
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12   F Oral 21/10/2019 Augmentin 
18/11/201
9 
18/11/2019 0   Well-tolerated  
13   F Nasal 22/10/2019 Augmentin 
18/11/201
9 
18/11/2019 0   Well-tolerated, tedious 
14   F Oral 22/10/2019 Augmentin 
18/11/201
9 
18/11/2019 0   Dry mouth, upset stomach, bloated 
15 # F Nasal 23/10/2019 Augmentin 
19/11/201
9 
19/11/2019 0 D4 Dry mouth, pungent sesame smell 
16   F Oral 23/10/2019 Augmentin 
19/11/201
9 
25/11/2019 6   Bloating  
17 # F Nasal 23/10/2019 Augmentin 
19/11/201
9 
19/11/2019 0 D4 
Nasal crusting and discharge, 
pipette build-up 
18   F Oral 23/10/2019 Augmentin 
19/11/201
9 
22/11/2019 3   Well-tolerated  
19   F Oral 23/10/2019 Augmentin 
19/11/201
9 
19/11/2019 0   Well-tolerated 
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20 # F Nasal 23/10/2019 Augmentin 
19/11/201
9 
19/11/2019 0 D5 Nasal crusting and discharge 
21   F Oral 25/10/2019 Augmentin 
22/11/201
9 
22/11/2019 0   Well-tolerated  
22   F Oral 25/10/2019 Augmentin 
22/11/201
9 
22/11/2019 0   Well-tolerated  
23   F Nasal 25/10/2019 Augmentin 
22/11/201
9 
22/11/2019 0   Well-tolerated  
24 # F Nasal 25/10/2019 Augmentin 
22/11/201
9 
22/11/2019 0 D4 
Tedious to do twice daily and 
having to lay down 
25   F Nasal 25/10/2019 Augmentin 
22/11/201
9 
22/11/2019 0   Tedious to do twice daily 
26   F Oral 25/10/2019 Augmentin 
22/11/201
9 
22/11/2019 0   Well-tolerated  
27   M Nasal 25/10/2019 Augmentin 
22/11/201
9 
25/11/2019 3   Difficult to tell volume used 
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28   F Oral 6/11/2019 Augmentin 3/12/2019 2/12/2019 -1   Bloating  
29   F Oral 6/11/2019 Augmentin 3/12/2019 3/12/2019 0   Well-tolerated 
30   F Oral 6/11/2019 Augmentin 3/12/2019 3/12/2019 0   Well-tolerated  
31   F Oral 6/11/2019 Augmentin 3/12/2019 2/12/2019 -1   
Well-tolerated but funny taste on 
waking the next morning 
32   F Nasal 6/11/2019 Augmentin 3/12/2019 3/12/2019 0   
Tedious at the end of 2 weeks, bad 
smell 
33   M Nasal 7/11/2019 Augmentin 4/12/2019 18/12/2019 14   Well-tolerated  
34   F Nasal 7/11/2019 Augmentin 4/12/2019 4/12/2019 0   Foul taste 
35   F Nasal 7/11/2019 Augmentin 4/12/2019 18/12/2019 14   Well-tolerated  
36   F Oral 7/11/2019 Augmentin 4/12/2019 4/12/2019 0   Well-tolerated  
37   F Nasal 7/11/2019 Augmentin 4/12/2019 18/12/2019 14   Foul taste 
38   F Oral 7/11/2019 Erythromycin 4/12/2019 4/12/2019 0   Well-tolerated  
39   M Oral 7/11/2019 Augmentin 4/12/2019 4/12/2019 0   Well-tolerated  
40   M Nasal 7/11/2019 Augmentin 4/12/2019 4/12/2019 0   Well-tolerated  
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41 # F Nasal 8/11/2019 Augmentin 5/12/2019       Lost to follow up 
42   F Oral 20/11/2019 Augmentin 
18/12/201
9 
23/12/2019 5   Well-tolerated  
43   F Nasal* 20/11/2019 Augmentin 
18/12/201
9 
18/12/2019 0   Foul taste 
44   F Oral 21/11/2019 Augmentin 
18/12/201
9 
19/12/2019 1   Well-tolerated   
45   F Nasal  21/11/2019 Augmentin 
19/12/201
9 
20/12/2019 1   Well-tolerated  
46   F Oral 21/11/2019 Augmentin 
19/12/201
9 
19/12/2019 0   Well-tolerated, pleasant taste 
47   F Nasal  21/11/2019 Augmentin 
19/12/201
9 
4/01/2020 16   Unpleasant to administer  
48   F Oral 21/11/2019 Augmentin 
19/12/201
9 
4/01/2020 16   Well-tolerated  
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49   M Oral 23/11/2019 Augmentin 
21/12/201
9 
23/03/2020 93   Poor compliance 
50 # F Nasal  23/11/2019 Erythromycin 
21/12/201
9 
4/01/2020 14 D5 
Poor compliance due to issue with 
taste  
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Information Sheet:  
ICON trial (Probiotics colonisation trial) 
You are invited to take part in a preliminary study to find out if giving BLIS probiotics using 
nasal drops is a feasible way to colonise the back of the nose (nasopharynx) with “healthy 
bacteria”. We aim to recruit 40 people into the study. The study will be conducted from May 
to June 2019. We would be grateful if you would read this information about the study and 
consider whether you would like to participate in this study. You may have a friend, family or 
whānau support to help you understand the risks and/or benefits of this study. We are also 
happy to answer questions or provide any explanation you may require. If you do not wish to 
be in this study, please let us know – this will not affect your health care provision in any shape 
way or form.  
The study is being carried out by research staff from the Canterbury District Health Board and 
the University of Otago, Christchurch.   
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About the Study 
Ear infections are common and will often lead to children needing multiple courses of 
antibiotics. In some children, surgery to insert grommets is one of the only options to prevent 
ongoing infections. We want to try to prevent these, and possibly prevent the need for surgery, 
by using probiotics. Probiotics are “healthy bacteria” that can help the body’s immune system 
fight infections.  
The aim of this study is to see how well BLIS probiotics given by nasal drops each day, alter 
the composition of the other bacteria on the back of the nose. We hope that giving probiotics 
this way will encourage the good bacteria (the probiotics) to become established in your nose 
– preventing recurrent ear infections.  
What’s involved 
We are inviting a group of healthy adult volunteers from Christchurch hospital to take part in 
the study. Taking part in this study does not affect your usual healthcare in any way. If you 
choose to take part, we will swab your nose at the start to collect the normal bacteria living 
there and give them a course of oral antibiotics, before starting on daily BLIS probiotics for 2 
weeks (these will be provided free of charge).  After completing the 2-week course, you will 
then have 5 days of rest. We will then take another swab from the back of your nose after the 
5 days’ rest. We will only collect bacteria from the nose and will not be collecting any tissue.  
The doctor who is in charge of your care in the hospital may not be directly involved in this 
study. However, they will be informed of your participation, but will not alter your treatment 
in any way. You will be reviewed in the Ear, Nose, and Throat (ENT) Department during the 
trial and should you develop an ear infection or any adverse effect while on the trial you would 
be seen by one of the trial Doctors as soon as possible.  
Tzu Yu Chen MMedSc 2022556 
136 
 
We would like your permission to: 
 Take a swab from the very back of your nose to determine the composition of the 
bacteria pre-existing to any intervention. 
 Give you a course of amoxicillin 500mg twice a day for 5 days (or if you are allergic 
to penicillin to give you 800mg of erythromycin twice a day for 5 days) 
 Give you a two-week course of BLIS probiotics in either the nasal drop form or the oral 
tablet form. 
 At the conclusion of the study, to take a further swab of the bacterial composition from 
the back of your nose. 
 Store any left-over sample obtained from you after testing for use in future, related 
research studies.  
(Further approval will be obtained from an accredited New Zealand Ethics Committee to do 
any other further tests on the samples you have provided.) 
Risks and Benefits 
The risks involved in this study are minimal. BLIS Probiotics are available currently in 
pharmacies in New Zealand to purchase and are considered to be safe. The bacteria used in 
BLIS probiotics are normal bacteria that live in our mouths – in fact, the original strain was 
identified from a school child in Dunedin. They do not normally cause disease.  
The antibiotics used in this trial are a short course and are no different from the ones commonly 
prescribed by your family doctor for ear, nose, throat or chest infections. Common side effect 
from the amoxicillin and erythromycin include nausea, vomiting, abdominal discomfort, 
diarrhoea, but it can have rare side effects causing liver or heart rhythm upsets. We, therefore, 
strongly encourage you to discuss this with the study investigators prior to starting the trial. 
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Nasopharyngeal swabs taken at the commencement or at the conclusion of the study will be 
carried out by an experienced and trained personnel. It is a very safe procedure but can be a bit 
uncomfortable; however, it certainly should not be painful; please advise the research staff 
immediately if the pain is experienced. The procedure can also be associated with a small risk 
of causing a nose bleed, however, can be exacerbated by blood thinners. If nose bleed were to 
happen, this will often settle with simple direct pressure and will be dealt with immediately. 
By participating in this study, you will be able to help us determine how effective it is to give 
probiotics by nasal drops in changing the usual make-up of bacteria in the back of the nose. 
This may benefit a lot of children with recurrent ear infections in the future.  
Participation and Confidentiality 
The study is not part of your routine health care and is for research purposes only. You can 
withdraw consent to take part in the study at any time without having to explain why. If you 
choose not to consent to participate in the study, it will not affect any current or future 
treatments. 
No material that could personally identify you will be used in any reports on this study. All 
information collected in this study is confidential and will not be available to anyone except 
the small team of researchers at Canterbury District Health Board and the University of Otago, 
Christchurch. The study staff will ensure that your anonymity is maintained. You will be 
identified by a study ID number.  All documents will be stored securely and only accessible by 
study staff and authorised personnel. Any data or samples that relate to you that leave the study 
site will be identified by a study number only. All potential future publication will also preserve 
your anonymity and will not contain any identifiable characteristics. 
Compensation: 
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If you are injured in this study, which is unlikely, you would be eligible to apply for 
compensation from ACC just as you would be if you were injured in an accident at work or at 
home. This does not mean that your claim will automatically be accepted. You will have to 
lodge a claim with ACC, which may take some time to assess. If your claim is accepted, you 
will receive funding to assist in your recovery.  
If you have private health or life insurance, you may wish to check with your insurer that taking 
part in this study won’t affect your cover.  
Contacts: 
If you would like to know more about the study or wish to ask any questions, please contact: 
Associate Professor Tony Walls, Department of Paediatrics, University of Otago, Christchurch 
Phone: 027269968 
Or 
Dr. Adam Tzu Yu Chen, Department of ENT, Christchurch Public Hospital 
Phone: 0212068999 
If you have any queries or concerns regarding your rights as a participant in this study, you 
may wish to contact an independent Health and Disability Advocate:  
Telephone:  0800 555 050    Email:  advocacy@advocacy.org.nz 
The study has received ethical approval from the Health and Disability Ethics Committee, New 
Zealand. Ethics approval number: 19/STH/117 
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I have read and understood the information sheet for people taking part in the study of the use 
of BLIS nasal drops in the colonisation of the nasopharynx. I have had the opportunity to discuss 
the study and am satisfied with the answers I have been given. 
 
I, _______________________________________ consent to participate in this study having 
understood the information that I have received.  
I have had the opportunity to use whanau support or a friend to help me ask questions and 
understand the study. 
I understand that taking part in this study is voluntary and that I can withdraw from the study 
at any time. This will not affect my continuing health care. 
I understand that my participation in this study is confidential and that no material that could 
identify me will be used in reports on this study. 
I understand that the information generated by this study will be stored for 10 years. 
I understand the compensation provisions for this study. 
I know whom to contact if I was to experience any side effects while on the study. 
I have had time to consider my participation in the study. 
I know whom to contact if I have any questions about the study in general.  
I give consent for the bacteria collected from my nose to be stored for future related research. 
 
YES    NO  
 If NO: I would like my samples to be:    
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Returned to me   
         
     Disposed of 
  
     Disposed of with Karakia/prayer 
I would like a copy of the results of the study once it is completed 
 




Signed: _________________________________ Date: _________________ 
 
Printed name: _________________________ 
 




Project explained by: ________________________________  





Project Role: _____________________________________________   
Date: ___________________ 
Researchers: 
Christchurch Team:  Dr Adam Tzu Yu Chen (Principal Investigator) 
Associate Professor Tony Walls (Paediatrician) 
   Associate Professor Philip Bird (ENT Specialist) 
   Mr Scott Stevenson (ENT Specialist) 
   Mr Sam Greig (ENT Specialist) 
   Dr Jonathan Williman (Biostatistician)  
